WO2004063221A1 - メタスチン誘導体およびその用途 - Google Patents
メタスチン誘導体およびその用途 Download PDFInfo
- Publication number
- WO2004063221A1 WO2004063221A1 PCT/JP2003/016978 JP0316978W WO2004063221A1 WO 2004063221 A1 WO2004063221 A1 WO 2004063221A1 JP 0316978 W JP0316978 W JP 0316978W WO 2004063221 A1 WO2004063221 A1 WO 2004063221A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- asn
- arg
- phe
- metastin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a derivative and a use thereof.
- Metastin derived from human also called KiSS-l peptide
- metastin derived from mouse rat WO 01 Z75104 04 2
- a sustained-release preparation containing metastin is also known (WO 02/83539).
- Metastin has a cancer metastasis inhibitory activity, and is used in cancer (eg, lung cancer, stomach cancer, liver cancer, knee cancer, colon cancer, rectum, colon cancer, prostate cancer, ovarian cancer, uterine cancer, breast cancer, kidney cancer) Effective for the prevention and treatment of bladder cancer, brain tumors, etc.). It has a function to regulate knee function, and is also used for the prevention and treatment of knee diseases (eg, acute or chronic knee inflammation, knee cancer, etc.).
- cancer eg, lung cancer, stomach cancer, liver cancer, knee cancer, colon cancer, rectum, colon cancer, prostate cancer, ovarian cancer, uterine cancer, breast cancer, kidney cancer
- knee diseases eg, acute or chronic knee inflammation, knee cancer, etc.
- An object of the present invention is to provide a stable metastin derivative having excellent cancer metastasis inhibitory activity, cancer growth inhibitory activity and the like.
- the present inventors have conducted intensive studies in order to solve the above-mentioned problems, and as a result, unexpectedly, by modifying the constituent amino acids of metastin with a specific modifying group, blood stability and the like are unexpectedly higher than that of natural metastin. Was found to be improved and exhibited excellent cancer metastasis inhibitory activity and cancer growth inhibitory activity. Furthermore, the present inventors have discovered that metastin and metastin derivatives have been unexpectedly conventionally known. It has been found to have a blood glucose increasing effect, a ⁇ glucagon secretion promoting effect, and a urine production promoting effect, which are completely different from the above effects. The present inventors have further studied based on these findings and completed the present invention.
- 2 1, Z 3, Z 5 and Z 7 each represent a hydrogen atom or a C E - 3 a ⁇ alkyl group
- z 2, z 4, z 6 and z 8 are each a hydrogen atom, o or
- R 1 is substituted with a group selected from the group consisting of (1) a hydrogen atom or (2) an optionally substituted rubamoyl group, an optionally substituted hydroxyl group, and an optionally substituted aromatic ring group.
- a C-alkyl group which may be
- R 2 is (1) a hydrogen atom or (2) a cyclic or chain C chain.
- R 3 has (1) a basic group which may be substituted, and a C ⁇ 8 alkyl group which may further have another substituent;
- Non-aromatic compounds having 7 or less carbon atoms having an optionally substituted basic group A C— 4 ′ alkyl group having an aromatic heterocyclic group and optionally having another substituent,
- R 4 is (1) an optionally substituted C 6 _ 12 aromatic hydrocarbon group
- an optionally substituted 5 to 14 membered aromatic heterocyclic group comprising 1 to 7 carbon atoms and a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom,
- (2) consists of 1 to 7 carbon atoms which may be substituted and a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom
- a C i- 4 alkyl which may be substituted with a substituent selected from the group consisting of an optionally substituted non-aromatic heterocyclic group having 7 or less carbon atoms
- Q 2 represents (1) CH 2 , which may be substituted with a C-4 alkyl group which may be substituted with a substituent selected from the group consisting of a rubamoyl group and a hydroxyl group, (2) NH or (3) O which may be substituted by a C- 4 alkyl group which may be substituted by a substituent selected from the group consisting of
- Y may be substituted with C i-e alkyl group, the formula - C ONH-, one CS NH-, one CH 2 NH-, one NHCO -, - CH 2 0-, - CH 2 S - or a A group represented by CH 2 CH 2 —
- Z 9 represents a hydrogen atom, O or S
- P is (1) a hydrogen atom
- SEQ ID NO any contiguous or discontinuous amino acid residue linked from the C-terminal side of amino acid sequence Nos. 1 to 48 of amino acid sequence represented by 1,
- J 1 may be substituted with a substituent containing an (a) hydrogen atom or (b) may have a substituent group ring group, (i) (: - 1 5 Ashiru group,
- J 2 represents (1) NH which may be substituted with a C i- 6 alkyl group, (2) CH 2 which may be substituted with a C i- 6 alkyl group, (3) O or (4) S ,
- J 3 to J 6 each represent a hydrogen atom or a C-3 alkyl group
- a 5- to 14-membered aromatic heterocyclic group comprising a hetero atom selected from the group consisting of an oxygen atom and a sulfur atom, (3) optionally substituted C 8 - 14 aromatic fused ring group,
- J 3 and Q 3 , J 4 and Q 4 , J 5 and Q 5 , J 6 and Q 6 , or J 2 and Q 3 , Y 1 and Q 4 , Y 2 and Q 5 , Y 3 and Q 6 may combine to form a ring
- ⁇ Yu ⁇ 3 one each CON (J 1 3) -, - CSN (J 1 3) -, - C (J 1 4) N (J 1 3) - or a N (J 1 3) CO- ( J 13 and J 14 each represent a hydrogen atom or a C alkyl group).
- Z 1 G represents a hydrogen atom, O or S), a group represented by
- J 7 to J 9 are the same as J 3
- Q 7 to Q 9 are the same as Q 3
- Y 2 and Y 3 are as defined above,
- J 7 and Q 7, J 8 and Q 8, J 9 and Q 9 are attached or forms a ring by J 2 and Q 7, Y 2 and Q 8, Y 3 and Q 9 are attached You may. ), A group represented by
- J 10 and J 11 are the same as J 3 ,
- Y 3 is as defined above
- J 12 is equivalent to J 3
- Q 12 is the same as Q 3
- J 1 2 and Q 1 2 are attached, or may form a ring by J 2 and Q 1 2 are attached.
- J 1 one (J 1 is as defined above) a group represented by.
- a metastin derivative (I) (provided that SEQ ID NO: 1 to 54, 2 to 54, 3 to 54, and 4 to 54 of the amino acid sequence represented by 1) , 5th to 54th, 6th to 54th, 7th to 54th, 8th to 54th, 9th to 54th, 10th to 54th, 11th to 5th , 1st 2nd to 5th 4th, 1st 3rd to 5th 4th, 14th to 5th 4th, 15th to 54th, 16th to 54th, 17th to 54th, 18th to 18th 5 4th, 19th to 54th, 20th to 54th, 21st to 54th, 22nd to 54th, 23rd to 54th, 24th to 54th 2nd, 5th to 54th, 26th to 54th, 27th to 54th, 28th to 54th, 2nd 9th to 54th, 30th to 54th, 31st to 54th, 32nd to 54th
- the medicament according to (4) which is a cancer metastasis inhibitor or a cancer growth inhibitor
- the medicament according to (4) above which is a prophylactic / therapeutic agent for choriocarcinoma, hydatidiform mole, invading mole, miscarriage, fetal growth deficiency, abnormal glucose metabolism, abnormal lipid metabolism, or induction of labor.
- [16] a method for inhibiting cancer metastasis or cancer growth, comprising administering to a mammal an effective amount of the metastin derivative (I) or a salt thereof or a prodrug thereof according to [1];
- [17] a method for preventing or treating cancer, which comprises administering to a mammal an effective amount of the metastin derivative (I) or a salt thereof or a prodrug thereof according to [1].
- [18] a method for regulating knee function, comprising administering to a mammal an effective amount of the metastin derivative (I) or a salt thereof or a prodrug thereof according to [1];
- [20] a method for regulating placental function, which comprises administering to a mammal an effective amount of the metastin derivative (I) or a salt thereof or a prodrug thereof according to [1];
- a method for improving gonadal function which comprises administering to a mammal an effective amount of the metastin derivative (I) or a salt thereof or a prodrug thereof according to the above [1].
- a hormone-dependent cancer eg, prostate cancer, breast cancer characterized by administering to a mammal an effective amount of the metastin derivative (I) or a salt thereof or a prodrug thereof according to [1].
- an effective amount of the metastin derivative (I) or a salt thereof or a prodrug thereof according to [1].
- a method of promoting gonadotropin secretion or a method of promoting sex hormone secretion comprising administering to a mammal an effective amount of the metastin derivative (I) or a salt thereof or a prodrug thereof according to [1].
- a method for preventing Alzheimer's disease or mild cognitive impairment which comprises administering to a mammal an effective amount of the metastin derivative (I) or a salt thereof or a prodrug thereof according to [1].
- a knee glucagon secretagogue comprising a metastin receptor agonist
- a urine production promoter comprising a metastin receptor agonist
- Obesity hyperlipidemia, type 2 diabetes, hypoglycemia, hypertension, diabetic neuropathy, diabetic nephropathy, diabetic nephropathy, diabetic retinopathy, edema, dysuria, insulin resistance containing metastin receptor agonist
- Prophylactic and therapeutic agents for gender unstable diabetes, lipoatrophy, insulin allergy, insulinoma, arteriosclerosis, thrombotic disease or lipotoxicity,
- metastin receptor agonist is the metastin derivative (I) or a salt or a prodrug thereof according to claim 1;
- (43) a method for promoting urine production, which comprises administering an effective amount of a metastin receptor agonist to a mammal;
- Prevention and treatment of nephropathy, diabetic retinopathy, edema, dysuria, insulin resistance, unstable diabetes, lipoatrophy, insulin allergy, insulinoma, arteriosclerosis, thrombotic disease or lipotoxicity Law Prevention and treatment of nephropathy, diabetic retinopathy, edema, dysuria, insulin resistance, unstable diabetes, lipoatrophy, insulin allergy, insulinoma, arteriosclerosis, thrombotic disease or lipotoxicity Law,
- Obesity hyperlipidemia, type 2 diabetes, hypoglycemia, hypertension, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, edema, dysuria, insulin resistance, unstable diabetes, lipoatrophy,
- a metastin receptor agonist for producing a prophylactic / therapeutic agent for insulin allergy, insulinoma, arteriosclerosis, thrombotic disease or lipotoxicity.
- a hyperglycemic agent comprising metastin or a salt thereof
- a knee glucagon secretion promoter comprising metastin or a salt thereof
- a urine production promoter comprising metastin or a salt thereof
- a hyperglycemic agent comprising DNA, which contains DNA encoding metastin
- glucagon secretagogue comprising DNA which contains DNA encoding metastin
- a urinary production promoter comprising DNA which contains DNA encoding metastin
- Obesity hyperlipidemia, type 2 diabetes, hypoglycemia, hypertension, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, edema, which contain DNA containing DNA encoding metastin Dysuria, insulin resistance, anxiety Prevention and treatment of diabetes mellitus, lipoatrophy, insulin allergy, insulinoma, arterial stiffness, thrombotic disease or lipotoxicity,
- hypoglycemic agent comprising an antibody against metastin or a salt thereof
- a knee glucagon secretion inhibitor comprising an antibody against metastin or a salt thereof
- a urine production inhibitor comprising an antibody against metastin or a salt thereof
- Diabetes glucose intolerance, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, frequent urination, nocturnal enuresis, hyperlipidemia, sexual dysfunction comprising antibodies to metastin or a salt thereof
- Prophylactic and therapeutic agents for skin diseases, joint disorders, osteopenia, arteriosclerosis, thrombotic diseases, indigestion or memory learning disorders
- a hypoglycemic agent comprising antisense DNA to DNA containing DNA encoding metastin
- a knee glucagon secretion inhibitor comprising antisense DNA to DNA containing DNA encoding metastin
- a urine production inhibitor comprising an antisense DNA to DNA containing metastin-encoding DNA
- a hyperglycemic agent comprising a metastin receptor or a salt thereof
- a tunnel glucagon secretion promoter comprising a metastin receptor or a salt thereof
- (22) a urine production promoter containing a metastin receptor or a salt thereof, (23) obesity, hyperlipidemia, type 2 diabetes, hypoglycemia containing a metastin receptor or a salt thereof, Hypertension, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, edema, dysuria, insulin resistance, unstable diabetes, fat Prophylactic and therapeutic agents for atrophy, insulin allergy, insulinoma, arteriosclerosis, thrombotic disease or lipotoxicity,
- a hyperglycemic agent comprising DNA, which comprises DNA encoding a metastin receptor
- a glucagon secretagogue comprising a DNA containing a DNA encoding a metastin receptor
- a urine production promoter comprising DNA containing DNA encoding a metastin receptor
- Obesity hyperlipidemia, type 2 diabetes, hypoglycemia, hypertension, diabetic neuropathy, diabetic nephropathy, diabetic nephropathy, diabetic retinopathy, edema containing DNA encoding the metastin receptor Dysuria, insulin resistance, unstable diabetes, lipoatrophy, insulin allergy, insulinoma, arteriosclerosis, thrombotic disease or lipotoxicity
- Obesity hyperlipidemia, hypoglycemia, hypertension, diabetic neuropathy, diabetic nephropathy, diabetic nephropathy, diabetic retinopathy, edema, dysuria containing DNA that encodes the metastin receptor , Insulin resistance, unstable glucoseuria, lipoatrophy, insulin allergy, insulinoma, arteriosclerosis, thrombotic disease, lipotoxicity, diabetes, impaired glucose tolerance, ketosis, acidosis, pollakiuria, nocturia, sexual dysfunction, skin Diagnostic agents for diseases, arthropathy, osteopenia, arterial stiffness, thrombotic diseases, dyspepsia or memory learning disorders,
- hypoglycemic agent comprising an antibody against the metastin receptor or a salt thereof
- a knee glucagon secretion inhibitor comprising an antibody against a metastin receptor or a salt thereof
- a urine production inhibitor comprising an antibody against a metastin receptor or a salt thereof
- Glucuria glucose intolerance, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy, diabetic nephropathy, diabetic retinopathy, pollakiuria, nocturia, hyperlipidemia containing an antibody against the metastin receptor or its salt Disease, sexual dysfunction, skin disease Prevention and treatment of illness, arthropathy, osteopenia, arteriosclerosis, thrombotic disease, dyspepsia or memory learning disorders,
- a hypoglycemic agent comprising antisense DNA to DNA containing metastin receptor-encoding DNA
- a knee glucagon secretion inhibitor comprising antisense DNA- against DNA containing DNA encoding the metastin receptor
- a urine production inhibitor comprising antisense DNA to DNA containing metastin receptor-encoding DNA
- Diabetes glucose intolerance, ketolysis, acidosis, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, which contains antisense DNA to DNA containing metastin receptor-encoding DNA, Prevention and treatment of frequent urination, nocturia, hyperlipidemia, sexual dysfunction, skin disease, arthropathy, osteopenia, arterial stiffness, thrombotic disease, indigestion or memory learning disorder,
- metastin receptor is a protein containing an amino acid sequence identical or substantially identical to the amino acid sequence represented by SEQ ID NO: 9, SEQ ID NO: 11 or SEQ ID NO: 13 [ 1) to the agent according to (22),
- a method of screening for a blood glucose modulator, an arm glucagon modulator or a urine formation modulator which comprises using metastin or a salt thereof and / or a metastin receptor, a partial peptide or a salt thereof,
- a method for screening a urine production regulator A method for screening a urine production regulator,
- a glycemic agent comprising a DNA containing DNA encoding metastin and / or a DNA containing DNA encoding a metastin receptor or a partial peptide thereof, Drug or urine production modulator screening kits,
- hypoglycemic agent comprising an antagonist to the metastin receptor
- knee glucagon secretion inhibitor comprising an engonist for metastin receptor
- a urinary growth inhibitor comprising an angonisto for a metastin receptor
- Diabetes glucose intolerance, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, frequent urination, nocturia, hyperlipidemia, sexual dysfunction containing an antagonist to metastin receptor , Skin diseases, arthropathy, osteopenia, arteriosclerosis, thrombotic diseases, indigestion or memory learning prevention and treatment agents,
- a hyperglycemic agent containing a substance that promotes the expression of metastin
- a knee glucagon secretion promoter containing a substance that promotes the expression of metastin
- Urine production promoter containing a substance that promotes metastin expression
- a hypoglycemic agent comprising a substance that inhibits metastin expression
- a glucagon secretion inhibitor comprising a substance that inhibits metastin expression
- a urine production inhibitor comprising a substance that suppresses the expression of metastin
- Diabetes impaired glucose tolerance, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy, glycemic retinopathy, frequent urination, nocturia, hyperlipidemia, which contain substances that inhibit the expression of metastin Prevention and treatment of sexual dysfunction, skin disease, arthropathy, osteopenia, arteriosclerosis, thrombotic disease, dyspepsia or memory learning disorder,
- a blood glucose enhancer comprising a substance that promotes the expression of metastin receptor
- a tunnel glucagon secretagogue comprising a substance that promotes the expression of metastin receptor
- a urine production promoter comprising a substance that promotes the expression of metastin receptor
- Obesity hyperlipidemia, type 2 diabetes, hypoglycemia, hypertension, diabetic neuropathy, diabetic nephropathy, diabetic nephropathy, diabetic retinopathy, edema, urination, which contain substances that promote metastin receptor expression Prevention and treatment of dysfunction, insulin resistance, unstable diabetes, lipoatrophy, insulin allergy, insulinoma, arteriosclerosis, thrombotic disease or lipotoxicity,
- a blood sugar lowering agent comprising a substance that suppresses the expression of metastin receptor
- glucagon secretion inhibitor comprising a substance that suppresses the expression of metastin receptor
- a urine production inhibitor comprising a substance that suppresses metastin receptor expression
- Diabetes impaired glucose tolerance, ketolysis, acidosis, diabetic neuropathy, diabetic kidney containing a substance that suppresses the expression of metastin receptor Prophylaxis, treatment for diabetic retinopathy, frequent urination, nocturia, hyperlipidemia, sexual dysfunction, skin disease, arthropathy, osteopenia, arteriosclerosis, thrombotic disease, indigestion or memory learning disorder,
- (6) a method for increasing blood glucose, which comprises administering an effective amount of a substance that promotes the expression of metastin receptor,
- (6) a method of promoting knee glucagon secretion, which comprises administering an effective amount of a substance that promotes the expression of metastin receptor;
- obesity hyperlipidemia, type 2 diabetes, hypoglycemia, hypertension, diabetic neuropathy, diabetic nephropathy, diabetic nephropathy, diabetic retina characterized by administering an effective amount of a substance that promotes metastin receptor expression Illness, edema, dysuria, insulin resistance, unstable diabetes, lipoatrophy, insulin allergy, insulino — Ma, arteriosclerosis, thrombotic diseases or lipotoxicity prevention and treatment methods, [66]
- a method for lowering blood glucose which comprises administering an effective amount of a substance that suppresses the expression of metastin receptor,
- a method for suppressing glucagon secretion of a knee which comprises administering an effective amount of a substance that suppresses the expression of metastin receptor;
- Diabetes impaired glucose tolerance, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, pollakiuria, characterized by administering an effective amount of a substance that suppresses the expression of metastin receptor.
- Obesity hyperlipidemia, type 2 diabetes, hypoglycemia, hypertension, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, edema, dysuria, insulin resistance, unstable diabetes, 'fat
- prophylactic and therapeutic agents for atrophy insulin allergy, insulinoma, arteriosclerosis, thrombotic disease or lipotoxicity
- Diabetes impaired glucose tolerance, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, frequent urination, nocturia, hyperlipidemia, sexual dysfunction, skin disease, arthropathy, osteopenia
- atherosclerosis impaired glucose tolerance, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, frequent urination, nocturia, hyperlipidemia, sexual dysfunction, skin disease, arthropathy, osteopenia
- atherosclerosis thrombotic diseases, dyspepsia or memory learning disorders
- metastin and / or metastin receptor (hereinafter also referred to as partial peptide) characterized by using a glycemic control agent, a knee glucagon modulator or a urine production modulator screening Method,
- a metastin receptor-activating compound for example, metastin, the metastin derivative (I) according to the above [1] or a salt thereof or a prodrug thereof
- a cell containing a metastin receptor eg, CH ⁇ cell The metastin receptor between a human colon cancer-derived cell line SW620 cell
- a metastin receptor-activating compound and a test compound when contacted with a cell containing the metastin receptor.
- a metastin receptor-activating compound for example, metastin, the metastin derivative (I) according to the above [1] or a salt thereof or a prodrug thereof
- a metastin receptor-activating compound for example, metastin, the metastin derivative (I) according to the above [1] or a salt thereof or a prodrug thereof
- a transformant that is brought into contact with a metastin receptor expressed on a cell membrane by culturing the transformant and a transformant containing a compound that activates the metastin receptor and a test compound that contains DNA encoding the metastin receptor Is characterized by measuring and comparing the metastin receptor-mediated cell stimulating activity when the cells are brought into contact with the metastin receptor expressed on the cell membrane by culturing the cells.
- a metastin receptor agonist characterized in that, when a test compound is brought into contact with a cell containing a metastin receptor, the cell stimulating activity mediated by the metastin receptor is measured and compared.
- Metastin receptor expressed on the cell membrane by culturing a transformant containing a test compound and DNA encoding the metastin receptor
- a method for screening a metastin receptor agonist which comprises measuring and comparing the cell stimulating activity mediated by the metastin receptor when brought into contact with the body,
- the cell stimulating activity is an activity of promoting intracellular Ca 2+ release, a cell growth inhibitory activity, a migration inhibitory activity, a tumor growth inhibitory activity, a blood glucose increasing activity, or a knee glucagon secretion promoting activity.
- ZZ 3 , Z 5 and Z 7 are each a hydrogen atom or a carbon atom.
- z 3 represents an alkyl group
- z 2 , z 4 , z 6 and z 8 each represent a hydrogen atom, o or S.
- alkyl group a methyl group, an ethyl group, a propyl group, and an isopropyl group are used.
- Z E ⁇ Z 8 by Z 1 and Z 3 is a hydrogen atom
- Z 5 and Z 7 are each a hydrogen atom or a C E - 3 alkyl group
- z 2, z 4, Z 6 and Z 8 is It is also preferable to show ⁇ or S, respectively.
- Z 1 is a hydrogen atom
- Z 3 is a hydrogen atom
- Z 5 is a hydrogen atom
- Z 7 is a hydrogen atom
- ⁇ 2 is 0, ⁇ 4 is 0,
- Z 6 is ⁇
- Z 8 is S If so,
- Z 1 and Z 3 are hydrogen atoms, Z 5 is a hydrogen atom, Z 7 is a methyl group, ⁇ 2 is ⁇ , ⁇ 4 is 0, ⁇ 6 is 0, Z 8 Is 0. Among them, the cases (a) and (b) are preferable.
- R 1 represents (1) a hydrogen atom or (2) an optionally substituted sorbamoyl group, an optionally substituted hydroxyl group, and an optionally substituted Represents a C-8 alkyl group which may be substituted with a group selected from the group consisting of aromatic ring groups, among which (1) a hydrogen atom or (2) an optionally substituted rubamoyl group, A C-8 alkyl group substituted with a group selected from the group consisting of an optionally substituted hydroxyl group and an optionally substituted aromatic ring group is preferred.
- alkyl group for example, methyl, Echiru, propyl, isopropyl, heptyl, Isopuchiru, sec- butyl, ter t-butyl, pentyl, isopentyl, chain neopentyl, hexyl, heptyl, etc.
- a C-3 alkyl group such as methyl and ethyl is preferable.
- force Luba moil for example, force Luba moil, mono- C _ 6 alkyl force Rubamoiru group (e.g., methyl carbamoylthiopheno Le, E Ji carbamoyl, etc.), di C - e alkyl force Rubamoiru group (eg, dimethylcarbamoyl, Jefferies Ji carbamoyl, E chill methyl Kalpa moil, etc.), mono- or di C 6 _ 4 ⁇ Li one carbamoyl group (e.g., phenylene carbamoyl, 1 one naphthylcarbamoyl, 2-Nafuchirukaru Bamoiru etc.), carbon A mono- or di- to 5-membered heterocyclic carpamoyl group containing one or two or one to four heteroatoms selected from nitrogen, sulfur and oxygen atoms in addition to the atom (eg, 2-pyridylcarbamoyl, 3—pyri
- hydroxyl group which may be substituted for example, hydro alkoxy group, an optionally substituted C i-6 alkoxy group, optionally substituted C 6 - 1 4 Ariruokishi groups, substituted A C 7 — i 6 aralkyl group is used.
- aromatic ring group in the “optionally substituted aromatic ring group” include, for example, an aromatic hydrocarbon group, an aromatic heterocyclic group, an aromatic fused ring group, and an aromatic condensed heterocyclic group. Are used.
- aromatic hydrocarbon group for example, phenyl, 2-Bifueniri Le, 3- Bifue two Lil, 4 Bifue two drill, the C 6 _ i 4 Ariru groups such as cyclopropyl O Kuta tetra E sulfonyl used.
- aromatic heterocyclic group examples include, for example, a 5- to 14-membered member containing one or two or one to four heteroatoms selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to a carbon atom, preferably Is a 5- to 10-membered, more preferably a 5- or 6-membered, aromatic heterocyclic group.
- chenyl eg, 2-phenyl, 3-phenyl
- frill eg, 2-furyl, 3-furyl
- pyridyl eg, 2-pyridyl, 3-pyridyl, 4-pyridyl
- Thiazolyl eg, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl
- oxazolyl eg, 2-oxazolyl, 4-oxazolyl
- pyrazinyl eg, 2-pyrimidinyl (eg, 2-pyrimidinyl, 4-pyrimidinyl)
- pyrrolyl Examples: 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), imidazolyl (eg, 1-imidazolyl, 2—imidazolyl, 4-—imidazolyl), pyrazolyl (eg, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), Pyridazinyl (eg, 3-pyrid
- aromatic fused ring group As the “aromatic fused ring group”, naphthyl (e.g., 1 one-naphthyl, 2-naphthyl), anthryl (e.g., 2 - anthryl, 9 one anthryl) C 8, such as - 1 4 aromatic condensed ring group with Can be
- aromatic fused heterocyclic group examples include, in addition to 3 to 11 carbon atoms, 1 or 2 types selected from nitrogen, sulfur and oxygen atoms, and 1 to 4 heteroatoms 5 to 14 members (preferably 5 to 14 members 10-membered) bicyclic or tricyclic aromatic heterocyclic group, or one or two selected from nitrogen, sulfur and oxygen atoms in addition to carbon atoms, including 1 to 4 heteroatoms 5
- a monovalent group formed by removing any one hydrogen atom from a 7 to 10-membered (preferably 5- to 10-membered) 7- to 10-membered aromatic hetero-bridged ring is used.
- quinolyl eg, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl
- isoquinolyl eg, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5 —Isoquinolyl
- indolyl eg, 1-indolyl, 2—indolyl, 3-indolyl
- 2-benzothiazolyl benzo [b] chenyl, (eg, 2-benzo [b] chenyl, 3-benzo [ b] Chenyl)
- furanyl eg, 2-benzo [b] furanyl, 3-benzo [b] furanyl
- R 1 for example, a hydrogen atom, forcerubamoylmethyl, 2-forceruboeruethyl, hydroxymethyl, 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-Chenylmethyl, 3-Chenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl, 3-indolemethyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclohexylmethyl, etc. are used.
- hydroxymethyl 1-hydroxyethyl, benzyl, 4-hydroxybenzyl, 3-indolemethyl, methyl, isobutyl and the like, and particularly preferred are hydroxymethyl, 1-hydroxyethyl and the like.
- R 2 is (1) a hydrogen atom, or (2) a cyclic or chain.
- alkyl group e.g., cyclopropyl, sik Robuchiru, cyclopentyl, C 3, such as cyclohexyl - 8 cycloalkyl And the like.
- chain-like alkyl group examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl.
- Nonanyl, decanyl and the like are used.
- C chain consisting of a cyclic alkyl group and a chain alkyl group.
- alkyl group examples include C 3 such as cyclopentylmethyl and cyclohexylmethyl.
- R 2 for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclohexylmethyl and the like are used, among which methyl, ethyl, isopropyl, isobutyl, sec-butyl, etc. , Tert-butyl and the like, and particularly preferably isopropyl, isobutyl and the like.
- R 3 has (1) a basic group which may be substituted, and a C i-s alkyl group which may further have another substituent;
- the "optionally substituted basic group” for example, (1) 1 or two C i-6 alkyl, - 6 Ashiru (e.g., methyl, Edjiru, propyl, isopropyl, butyl, Asechiru, A guanidino group which may have (2) 1 to 3 C alkyl, Ci- 6 acyl (eg, methyl, ethyl, propyl, isopropyl, butyl, acetyl, propionyl, etc.) An amino group which may have (3 PT / JP2003 / 016978
- guanidino group which may have 1 or 2 C- 6 alkyl, 6-acyl (eg, methyl, ethyl, propyl, isopropyl, butyl, acetyl, propionyl, etc.).
- C _ 6 Al kill force Lupo two Ruamino group eg, Asetoami de
- (4) 1 to 3 C i-6 alkyl, ⁇ - 6 Ashiru e.g., methyl, Echiru, propyl, I an isopropyl, butyl
- a C alkylcarbonylamino group eg, acetoamide which may be substituted with an amino group which may have acetyl, propionyl, etc. is used.
- guanidino N—methyldanidino, N, N—dimethyldanidino, N, N′-dimethyldanidino, N—ethylethylanidino, N—acetylguanidino, amino, N—methylamino, N, N—dimethylamino, aminoacetamine Mid, guanidinoacetamide, amidino and the like are preferred.
- (—8 alkyl group) includes, for example, methyl, ethyl, propyl
- aralkyl group examples include benzyl, phenyl, diphenylmethyl, 1-naphthylmethyl, 2-naphthylmethyl, 2,2-diphenylethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl, 2 - Bifue two Rirumechiru, 3 Bifue two Rirumechiru and C 7- E 6 Ararukiru group such as 4-Biff Eni Lil methyl is used.
- non-aromatic cyclic hydrocarbon group having 7 or less carbon for example, consequent opening, cyclobutyl, cyclopentyl, C 3, such as cyclohexyl - such cycloalkyl groups are used.
- non-aromatic heterocyclic group having 7 or less carbon atoms examples include, for example, one or two or one to four selected from nitrogen, sulfur and oxygen atoms in addition to one to seven carbon atoms.
- 5- to 10-membered non-aromatic compound containing hetero atom A ring group or the like is used.
- pyrrolidinyl eg, 11-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl
- oxazolidinyl eg, 2-oxazolidinyl
- imidazolinyl eg, 1-imidazolinyl, 2-imidazolinyl, 4-imidazolinyl
- piperidinyl eg, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl
- piperazinyl eg, 1-piperaziel, 2-piperazinyl
- morpholino e.g, 1-piperaziel, 2-piperazinyl
- thiomorpholino e.
- the - "4 alkyl group ( ⁇ " for example, methyl, Echiru, propyl, isopropyl, butyl, isobutyl, sec- butyl, tert - heptyl and the like.
- R 3 examples include (1) 3-guanidinopropyl, 3- (N-methyldanidino) propyl, 3- (N, N-dimethyldanidino) pill, 3- (N, N'-) Dimethyldanidino) propyl, 3- (N-ethylguanidino) propyl, 3_ (N-propylguanidino) propyl, 3-(N-acetyldanidino) propyl, 4-guanidinobutyl -(N-methyldanidino) butyl, 2-guanidinoethyl, 2 _ (N-methyldanidino) ethyl, 4-aminobutyl, 4- (N-methylamino) butyl, 4- (N, N-dimethylamino) butyl, 3-amino Propyl, 2-aminoethyl, aminomethyl, aminoacetamidomethyl, guanidinoacetamidomethyl, 2- (guanidinocarbonyl)
- 1-Amidinopiperidine-1-ylmethyl and the like are used, among which 3-guanidinopropyl, 3- (N-methyldanidino) propyl, 3- (N, N-dimethylguanidino) propyl, 3— (N , N'-Dimethyldanidino) propyl, 3- (N-ethylguanidino) propyl, 3- (N-propylguanidino) propyl, 3- (N-acetyldanidino) propyl, 4-guanidinobutyl, 4- (N- Methyldanidibutyl, 2-guanidinoethyl, 2- (N-methyldanidino) Butyl, 4-aminobutyl, 4- (N-methylamino) butyl, 4- (N, N-dimethylamino) butyl, 3-aminopropyl, 2-aminoethyl, 4-aminobenzyl, aminoacetamidomethyl, 2-a
- R 4 is an optionally (1) substituted C 6 - 12 aromatic hydrocarbon group
- an optionally substituted 5 to 14 membered aromatic heterocyclic group comprising 1 to 7 carbon atoms and a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom,
- (2) consists of 1 to 7 carbon atoms which may be substituted and a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom
- E 4 alkyl group for example, methyl, Edjiru, propyl, isopropyl, heptyl, isobutyl, s EC- butyl, ter t-butyl and the like.
- C 6 1 2 aromatic hydrocarbon group for example, phenyl, etc. monocyclic C 6- Interview 2 aromatic hydrocarbon groups such as cycloalkyl O Kuta tetra E sulfonyl are needed use.
- Examples of the "5- to 14-membered aromatic heterocyclic group comprising 1 to 7 carbon atoms and a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom” include, for example, 1 to 7 5 to 14 members, preferably 5 to 10 members, more preferably 5 to 5, including 1 or 2 and 1 to 4 hetero atoms selected from nitrogen atom, sulfur atom and oxygen atom other than carbon atom Alternatively, a 6-membered monocyclic aromatic heterocyclic group is used.
- chenyl eg, 2-Chenyl, 3-Chenyl
- frill eg, 2-furyl, 3-furyl
- pyridyl eg, 2-pyridyl, 3-pyridyl, 4-pyridyl
- thiazolyl Eg, 2-thiazolyl, 4- thiazolyl, 5-thiazolyl
- oxazolyl eg, 2-oxazolyl, 4-oxosazolyl
- pyrazinyl pyrimidinyl (eg, 2- pyrimidinyl, 4- pyrimidinyl)
- pyrrolyl eg, 1 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl
- imidazolysole eg, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl
- pyrazolyl eg, 1-pyrazolyl, 3-birazolyl, 4-pyrazolyl
- the - "1 4 aromatic fused ring group C 8" for example, naphthyl (e.g., 1 one-naphthyl, 2 one-naphthyl), anthryl (e.g., 2 - anthryl, 9 - 7 Nsuriru) and the like.
- Examples of the "5- to 14-membered aromatic condensed heterocyclic group comprising 3 to 11 carbon atoms and a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom” include, for example, 3 to 1 5- or 14-membered (preferably 5- to 10-membered) 2- or 1- or 2-membered atom selected from nitrogen atom, sulfur atom and oxygen atom in addition to 1 carbon atom 5- or 14-membered ring or tricyclic aromatic heterocyclic group, or one or two selected from nitrogen, sulfur and oxygen atoms, and one to four heteroatoms in addition to carbon atoms ( A monovalent group formed by removing any one hydrogen atom from a 7 to 10-membered aromatic hetero-bridged ring (preferably 5 to 10 members) is used.
- quinolyl eg, 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 8-quinolyl
- isoquinolyl eg, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-) Isoquinolyl
- indolyl eg, 1-indolyl, 2—indolyl, 3—indolyl
- 2-benzothiazolyl benzo [b] chenyl, (eg, 2-benzo [b] chenyl, 3-benzo [b] Chenyl), benzo [b] furanyl (eg, 2-benzo [b] furanel, 3-venzo [b] furanyl) and the like are used.
- non-aromatic cyclic hydrocarbon group having 7 or less carbon atoms for example, consequent opening, cyclobutyl, cyclopentyl, C 3 _ 7 consequent opening alkyl groups such as cyclohexyl may be used.
- non-aromatic heterocyclic group having 7 or less carbon atoms examples include pyrrolidinyl (eg, 1-pyrrolidiel, 2-pyrrolidinyl, 3-pyrrolidinyl), oxazolidinyl (eg, 2-oxazolidinyl), imidazolinyl (eg, 1-y) Midazolinyl, 2-imidazolinyl, 4-imidazolinyl), piberidinyl (eg, 1-piperidinyl, 2-piberidinyl, 3-piberidinyl, 4-piberidinyl), piperazinyl (eg, 1-piperazinyl, 2-pipi) 5 to 10 members including 1 to 2 types selected from nitrogen, sulfur and oxygen atoms, and 1 to 4 heteroatoms in addition to 1 to 7 carbon atoms such as radinyl), morpholino and thiomorpholino Non-aromatic heterocyclic groups and the like are used.
- C 6 _ 1 2 aromatic hydrocarbon group "1 to 7 carbon atoms and nitrogen atoms, 5 to 1 4-membered aromatic heterocyclic comprising a heteroatom selected from the group consisting of an oxygen atom and a sulfur atom ring group "," C 8 - 14 aromatic fused ring group "," 3 to 1 1 carbon atoms and nitrogen atoms, 5 to consist of a hetero atom selected from the group consisting of oxygen atom and sulfur atom 1 4
- Substituents of the "membered aromatic condensed heterocyclic group”, “non-aromatic cyclic hydrocarbon group having 7 or less carbon atoms” and “non-aromatic heterocyclic group having 7 or less carbon atoms” include, for example, oxo and halogen atoms.
- alkylamino eg, cyclopropylamino, cyclohexylamino
- C 6 — 4 arylamino eg, phenylamino, diphenylamino, naphthylamino
- Ci-6 alcohol Xylamino eg, methoxyamino, ethoxyamino, propoxyamino, isopropoxyamino
- formylamino optionally substituted C i-ealkyl mono-alkenylamino (eg, acetylamino, propionylamino, vivaloylamino, etc.), substituted which may be C 3 - 8 cycloalkyl Ichiriki Ruponiruamino (e.g., cyclopropyl force Lupo two Ruamino, cyclopentyl Luca Lupo sulfonyl ⁇ Mino, Kishirukarupo two Ruamino
- substituent group A for example optionally substituted C, - 6 alkoxy Ichiriki Ruponiru (e.g., Main Tokishikaruponiru, ethoxycarbonyl, propoxycarbonyl, ter t-butoxycarbonyl, etc.), optionally substituted (: 6 - 1 4 Ariru Okishi Ichiriki Ruponiru (eg, etc.
- Substituent group A may be substituted - 6 alkyl" - 6
- the ⁇ alkyl for example methyl, Echiru, propyl, isopropyl, heptyl, Isopuchiru, sec- butyl, tert - butyl, pentyl, Isopen Chill , Neopentyl, hexyl and the like are used.
- C 2 _ 6 alkenyl in the Substituent Group A -
- C 2 6 alkenyl include vinyl, propenyl, isopropenyl, 2-butene one 1 one I le, 4 One pentene, one pentane and five hexene are used.
- Substituent Group A "substituted (: 6 - 1 4 Ariru” in - as the “C 6 4 Ariru", for example phenyl, 1 one-naphthyl, 2-naphthyl, 2-Bifue two drill, 3- Biphenyl, 4-biphenyl, 2-anthryl and the like are used.
- C 7 of the optionally substituted C 6 Ararukiru "substituent group A -
- Examples of “(— 6 alkoxy)” of “optionally substituted C 6 alkoxy” in the substituent group A include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, pentyloxy, hexyloxy and the like. Is used.
- Substituent group A as "optionally substituted C 7 1 6 Ararukiruokishi" of ⁇ C 7 "! 6 Ararukiruokishi", for example, Benjiruokishi and off Enechiruokishi is used.
- Substituent Group A of "optionally substituted C 6 alkylthio", "(: ⁇ - 6 alkylthio” includes, for example, methylthio, Echiruchio, propyl thio, isopropylthio, butylthio, sec- butylthio, tert- butyl Lucio etc. Is used.
- C ⁇ - 6 alkyl force Rubamoiru di C E - 6 alkyl force Rubamoiru, mono - or di c 6 - i 4 ⁇ Li one carbamoyl, nitrogen atom in addition to carbon atom, 1 or 2 species selected from nitrogen and oxygen atoms And 1 to 5 substituents selected from mono- or di- or 5- to 7-membered heterocyclic compounds containing 1 to 4 hetero atoms, such as rubamoyl.
- Examples of the “optionally substituted heterocyclic group” in the substituent group A include a halogen atom, hydroxy, carbonyl, nitro, cyano, the above-mentioned optionally substituted Ci- 6 alkyl, optionally substituted C 2 - 6 alkenyl, the above-mentioned optionally substituted C 2 _ 6 alkynyl, upper noted was optionally substituted C 3 _ 8 cycloalkyl, optionally substituted and the C 6 _ 4 ⁇ Li Ichiru, optionally substituted and the C - 6 alkoxy, the above-mentioned optionally substituted C i _ 6 alkylthio, the above-mentioned optionally substituted C 6 even though - i 4 ⁇ Li one Lucio, optionally substituted and the C 7 - E 6 Ararukiruchio, optionally substituted and the C ⁇ - 6 alkylsulfinyl, optionally substituted and the C 6 - 1 4 ⁇ Li one Ru
- Group heterocyclic group is preferably used et. Specifically, for example, chenyl (eg, 2-phenyl, 3-phenyl), frills (eg, 2-furyl, 3-furyl), pyridyl (eg, 2-pyridyl, 3-pyridyl, 4-pyridyl), Thiazolyl (eg, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), oxazolyl (eg, 2-oxosazolyl, 4-year-old xazolyl), quinolyl (eg, 2-quinolinyl, 3-quinolyl, 4-quinolyl) , 5-quinolyl, 8-quinolyl), isoquinolyl (eg, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl), pyrazinyl, pyrimidinyl (eg, 2-pyrimidinyl, 4-pyrimidinyl), pyrrolyl (eg
- the above-mentioned optionally substituted Ci- 6 alkyl As the “optionally substituted amino” of the substituent group A, the above-mentioned optionally substituted Ci- 6 alkyl, the above-mentioned optionally substituted C 2 - 6 alkenyl, the above-mentioned optionally substituted C 2 _ 6 alkynyl, above optionally substituted noted C 3 - 8 cycloalkyl, optionally substituted and the C 6- i 4 ⁇ Li Ichiru above-mentioned optionally substituted C 1 _ 6 alkoxy, formyl, the optionally C E -e alkyl Ichiriki substituted with Ruponiru, optionally substituted and the C 3 - 8 cycloalkyl - carbonyl, the above-mentioned optionally substituted C 6 _ 14 Ariru Ichiriki Lupo nil, the above-mentioned optionally substituted C i-e alkoxy Ichiriki Ruponiru the
- C 6 _ 1 2 aromatic hydrocarbon group "1 to 7 carbon atoms and nitrogen atoms, 5 to consist of a hetero atom selected from the group consisting of an oxygen atom and a sulfur atom 1 4- aromatic heterocyclic group ", and a" C S _ 14 Kaoru aromatic fused ring group "," 3 to 1 1 carbon atoms and a nitrogen atom, an oxygen atom Contact and heteroatoms selected from the group consisting of sulfur atoms
- substituent of the 5- to 14-membered fused aromatic heterocyclic group, the non-aromatic cyclic hydrocarbon group J having 7 or less carbon atoms and the non-aromatic heterocyclic group having 7 or less carbon atoms include a halogen atom , hydroxy, C ⁇ - 6 alkoxy, but it may also be halogenated - 6 alkyl, optionally halogenated good C i_ 6 alkoxy, ⁇ amino, nitro, etc. Shiano are preferable.
- the R 4 for example,
- C i- 4 alkyl group having an optionally substituted non-aromatic cyclic hydrocarbon group having 7 or less carbon atoms such as cyclohexylmethyl, cyclopentylmethyl, indan-2-ylmethyl,
- C- 4 alkyl groups having a non-aromatic heterocyclic group are used, among which benzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 4-hydroxybenzyl, 4-aminobenzyl, 4-nitrobenzyl , 4 monochlorobenzyl, 4-methoxybenzyl, 4-cyanobenzyl, 3-trifluoromethylbenzyl, 3,4-dichlorobenzyl, 3,4-difluorobenzyl, pentafluorobenzyl, 3-pyridylmethyl , 4 -Pyridylmethyl, 3 -Indylmethyl, 1 -Formylindole-3 -
- Q 1 is (1) an optionally substituted C 6 _ 12 aromatic hydrocarbon group, (2) may be substituted, and 1 to 7 carbon atoms, a nitrogen atom, oxygen atom and sulfur atom
- a C- 4 alkyl group having a non-aromatic heterocyclic group is used, among which cyclohexylmethyl, benzyl, 4-fluorobenzyl, 4-hydroxybenzyl, pentafluorobenzyl, 2-pyridylmethyl, 4 Preferred are 1-pyridylmethyl, 1-naphthylmethyl, 2-naphthylmethyl and the like, particularly preferred are benzyl, 4-fluorobenzyl and cyclohexylmethyl.
- Q 2 represents (1) CH 2 which may be substituted with a C-4 alkyl group which may be substituted with a substituent selected from the group consisting of a carbamoyl group and a hydroxy group; A group consisting of hydroxy groups And NH or (3) 0 which may be substituted with a C-4 alkyl group which may be substituted with a substituent selected from the group consisting of:
- (: 4- alkyl group) for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like are used.
- Q 2 is preferably CH 2 , CH (CH 3 ), CH (CH 2 OH), NH or the like.
- Y is C - may be substituted with alkyl group, wherein one CONH-, - CS NH-, - CH 2 NH-, -NHC O-, one CH 2 0-, one CH 2 S one or a CH 2 represents a group represented by CH 2 —.
- rC i-e alkyl group examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl and the like.
- Y is preferably a group represented by the formulas: CONH—, CS NH—, NHCO—, and CH 2 NH—.
- Z 9 represents a hydrogen atom, O or S, with 0 and S being particularly preferred.
- P is (1) a hydrogen atom,
- SEQ ID NO any continuous or discontinuous amino acid residue linked from the C-terminal side of the 1st to 48th amino acid sequence of the amino acid sequence represented by 1 (54 amino acid residues of human metastin) ,
- a group represented by the formula J 1 — (J 1 has the same meaning as described above).
- Specific examples of the “amino acid residue linked continuously or discontinuously from the C-terminal side of the 1st to 48th amino acid sequence of the amino acid sequence represented by SEQ ID NO: 1” include:
- (22) lie Pro Ala Pro Gin Gly Ala Val Leu Val Gin Arg Glu Lys Asp Leu Pro Asn Tyr Asn Trp Asn-,
- Arg Gin lie Pro Ala Pro Gin Gly Ala Val Leu Val Gin Arg Glu Lys Asp Leu Pro Asn Tyr Asn Trp Asn-,
- J 1 may be substituted by (a) a hydrogen atom or (b) a substituent containing a ring group which may have a substituent, (i) a ( 15- acyl group, (ii) alkyl group, (iii) C 6 14 Ariru group, (iv) force Rubamoi Le group, (V) a carboxyl group, a (vi) sulfino group, (vii) amidino group or (viii) Dario xylo-yl group.
- the “ring group” include “optionally substituted aromatic hydrocarbon group”, “optionally substituted aromatic heterocyclic group”, and “optionally substituted aromatic fused ring group”.
- aromatic heterocyclic group As the “aromatic heterocyclic group”, the “aromatic condensed cyclic group”, and the “aromatic condensed heterocyclic group”, the same as those described above are used.
- non-aromatic cyclic hydrocarbon group cyclopropyl, Shikuropuchi Le, cyclopentyl, C 3, such as cyclohexyl - etc. 8 cycloalkyl group is used.
- Non-aromatic heterocyclic group includes pyrrolidinyl (eg, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl), oxazolidinyl (eg, 2-oxazolidinyl), imidazolinyl (eg, 1-imidazolinyl, 2-imidazolinyl, 4 1-imidazolinyl), piperidinyl (eg, 1 piperidinyl, 2-piperidinyl, 3-piberidinyl, 4-piperidinyl), piperazinyl (eg, 1-piperazinyl, 2-piperazinyl), morpholino, thiomorpholino, etc.
- pyrrolidinyl eg, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl
- oxazolidinyl eg, 2-oxazolidinyl
- imidazolinyl eg, 1-imi
- E 1 5 Ashiru group for example, formyl, (: E - 1 4 alkyl Rukaruponiru (eg, Asechiru, propionyl, C i-6 alkyl such Pibaroiru etc. - carbonyl) and the like.
- rCi- 15 alkyl group examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl , Nonanyl, decanyl and the like are used.
- the - "C 6 14 Ariru group” for example, phenyl, 1 one-naphthyl, 2-naphthyl, biphenyl is used.
- a C substituted with a substituent containing a cyclic group - is a 5 Ashiru group, (i) formyl, (ii) C 14 alkyl Ichiriki Ruponiru (eg, ⁇ cetyl, propionyl, Piparoiru etc. etc.
- C E - 6 alkyl Ichiriki Lupo two Le (iii) C 3 - 8 cycloalkyl - Karuponiru (eg, Shikuropuropi Rukaruponiru, cyclopentylcarbonyl, Kishirukaruponiru cyclohexane, Kishirukaruponiru like to 1 over methylcyclopentadienyl), (iv) C 3 — 8 cycloalkyl-C i _ 6 alkyl mono-propionyl (eg, cyclopropyl acetyl, cyclopentyl acetyl, cyclohexyl acetyl, etc.) (V) C 6 — 14 aryl mono-propionyl (eg, benzoyl, 1-naphthoyl) , 2-naphtho I le, etc.), C 6 _ 14 Ararukiru Ichiriki Ruponiru
- (2) is a substituted C over 5 optionally alkyl with a substituent containing a cyclic group, for example, (i) a mono- or di-C i _ 5 alkyl (e.g., methylation, Echiru, propyl, isopropyl Butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonanyl, decanyl), (ii) mono or dimono One C 3 - 8 cycloalkyl (e.g., cyclopropyl, cyclopentyl, etc.), (iii) mono - or di C 3 - 8 cycloalkyl one C 7 alkyl (for example, cyclopropylmethyl, cyclopentylmethyl, Kishirue chill like cyclohexane ), (iv
- Is a 14 Ariru groups e.g., (i) C 6 - - (3) 6 to Ji may be substituted with a substituent containing a cyclic group 14 Hajime Tamaki (e.g., cycloalkyl, Hue alkylsulfonyl, 1 one Naphthyl, 2-naphthyl, etc.), (ii) 5- to 7-membered monocyclic heterocycle containing one or two or one to four heteroatoms selected from nitrogen atom, sulfur atom and oxygen atom in addition to carbon atom A ring group (eg, 3-pyridyl, 2-phenyl, etc.), (iii) one or two or one to four selected from nitrogen, sulfur and oxygen atoms in addition to 3 to 11 carbon atoms
- a 5- to 14-membered (preferably 5- to 10-membered) bicyclic or tricyclic aromatic heterocyclic group containing a terrorist atom eg, 2-indolyl, 3-indolinyl
- the rubamoyl group which may be substituted with a substituent containing a ring group includes (i) rubamoyl, (ii) mono- or di-C- 5- alkylcarbamoyl groups (eg, methylcarbamoyl, Ji carbamoyl, (iii) mono- or di-one C 3 _ 8 cycloalkyl Ichiriki Rubamoiru (eg, Shikuropu port pills force Rubamoiru, cyclopentylcarbamoyl, Kishiruka Rubamoiru like cyclohexane), (iv) mono- or di-one C 3 _ 8 cycloalkyl alkyl one C ⁇ _ 6 alkyl Ichiriki Rubamoiru (e.g., consequent opening propyl methyl carbamoylthiopheno Le, cyclopentyl methylcarbamoyl, Kishiruechiruka Rubamoiru like to 2-cyclopropyl) (V
- a 5- to 7-membered monocyclic heterocyclic rubamoyl (eg, 3-pyridine rubamoyl, 2-thiophene rubamoyl, piperidin-3-ylcarbamoyl, etc.), (vii) a nitrogen atom other than a carbon atom A mono- or di- or 5- to 7-membered monocyclic heterocyclic ring containing 1 or 2 or 1 to 4 heteroatoms selected from sulfur atoms and oxygen atoms; , 3-pyridylmethylcarbamoyl, 2- (pyridine-1-yl) ethyl ethyl carbamoyl, 2— (piperidine-11-yl) ethylcarbamoyl, etc.), (viii) in addition to 3 to 11 carbon atoms Nitrogen atom, sulfur atom A mono- or di- or 5- to 14-membered (preferably 5- to 10-membered) two- or three-ring mono- or di-containing one or two selected from oxygen atoms
- Examples of the dalioxyloyl group which may be substituted with a substituent containing a ring group include (i) C i- 5 alkyloxalyl (C i- 5 alkyl here is a ring And a C- 5 alkyl group which may be substituted with a substituent containing a group, having the same meaning as that of the "rct- 15 alkyl group".
- C i- 5 alkyl here is a ring
- a C- 5 alkyl group which may be substituted with a substituent containing a group having the same meaning as that of the "rct- 15 alkyl group”.
- ethyl oxalyl ethyl oxalyl
- C 6 — 14 aryloxalyl (ii) C 6 — 14 aryloxalyl (C 6 — 4 aryl as referred to herein means “C” in “C 6 — 14 7 reel group which may be substituted with a substituent containing a ring group.”
- J 1 hydrogen atom, acetyl, 3-indolecarbonyl, 3- (indole-3-yl) propionyl, 3-phenylpropionyl, diphenylacetyl, 3- (pyridine-3-yl) Propionyl, 4-imidazole acetyl, cyclohexanecarponyl, 1-piperidine acetyl, 1-methyl-1-piperidinioacetyl, 4-piperidin-l-ponyl, hexanoyl, amino- (4-hydroxyphenyl) acetyl, D-dalcuronyl, 2 — (Indole-3-yl) ethylcarbamoyl, tert-butyloxyl-proponyl, 9-fluorenylmethoxycarbonyl, amidino, etc.
- J 2 represents a S (1) C Bok 6 alkyl optionally substituted by a group NH (2) C 6 alkyl optionally substituted with a group CH 2 (3) 0 or (4).
- rCi-e alkyl group examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl and the like.
- J 3 J 12 represents a hydrogen atom or a —3 alkyl group, respectively.
- rCi-s alkyl group methyl, ethyl, propyl, and isopropyl pill are used.
- the J 5, hydrogen atoms are preferable.
- an optionally substituted 5 to 14 membered aromatic heterocyclic group comprising 1 to 7 carbon atoms and a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom,
- Optionally substituted c 6 - 1 2 aromatic hydrocarbon group "heteroaryl selected from the group consisting of 1 to optionally substituted to 7 carbon atoms and a nitrogen atom, oxygen atom and sulfur atom 5 to consist of the atomic 1 4-membered aromatic heterocyclic group "," optionally substituted C 8 - 1 4 aromatic fused ring group ", 3- or may be” replacement to 1 1 carbon
- a 5- to 14-membered fused aromatic heterocyclic group comprising an atom and a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, and a ⁇ non-aromatic group having 7 or less carbon atoms which may be substituted ''
- the “cyclic hydrocarbon group” and the “optionally substituted non-aromatic heterocyclic group having 7 or less carbon atoms” the same as those described above are used.
- the C _ 4 alkyl group having a i 2 aromatic hydrocarbon group such as benzyl, 4-hydroxybenzyl, 2 - - (1) an optionally substituted C s black port benzyl, 3- black port Benzyl, 4-cyclobenzyl, 4-aminobenzil and the like are used.
- C e _ 4 alkyl group having a 5- to 14-membered aromatic heterocyclic group consisting of 1 to 7 carbon atoms which may be substituted and a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom the C e _ 4 alkyl group are, if example embodiment, 2 - pyridylmethyl, 3 - pyridylmethyl, 4 one pyridylmethyl, 4 - etc. imidazo one Rumechiru is used.
- a 5- to 14-membered aromatic fused heterocyclic group comprising an optionally substituted 3 to 11 carbon atoms and a heteroatom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom;
- Examples of the possessed —4 alkyl group include 3-indolemethyl, 1-formylindole-3-ylmethyl, 2-quinolylmethyl and the like.
- Examples of the C- 4 alkyl group having an optionally substituted amino group include 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 4-acetamidobutyl and the like. .
- Ci- 4 alkyl group having a propyloxyl group which may be substituted, for example, carboxylmethyl, 2-carboxylethyl, benzyloxycarbonylmethyl and the like are used.
- Ci- 4 alkyl group having an optionally substituted carbamoyl group for example, carbamoylmethyl, 2-carbamoylethyl, xanthylcarbamoyl and the like are used.
- C- 4 alkyl group which may be substituted and has a sulfhydryl group for example, sulfhydrylmethyl, 2- (methylsulfhydryl) ethyl and the like are used.
- C-4 alkyl group for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and the like are used.
- potassium rubamoyl methyl, 2-hydroxy rubamoyl ethyl, 4-hydroxybenzyl, 4-imidazolemethyl, isoptyl, hydroxymethyl, 1-hydroxyethyl, potassium propyloxymethyl, 4-aminobutyl, etc. are preferably used.
- Rubamoylmethyl, 2-force rubamoylethyl, 4-hydroxybenzyl and the like are preferably used.
- Q 5 includes benzyl, 2-cyclopentyl, 3-clobenzyl, 4-cyclobenzyl, 4-aminobenzyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 1-naphthylmethyl, 2 —Naphthylmethyl, 3—indolemethyl, 1-formylindole-3-ylmethyl, 2-quinolylmethyl, cyclohexylmethyl, hydroxymethyl, 1-hydroxyethyl, methyl, isopropyl, isoptyl, sec-butyl, propyloxymethyl, 4 Monoaminobutyl and the like are preferably used, and in particular, benzyl, 2-chlorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 4-aminobenzyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 1-naphthylmethyl, 2-naphthylmethyl
- methyl, hydroxymethyl, 1-hydroxyethyl, phorbamoylmethyl, 2-rrubamoylethyl and the like are preferably used, and particularly rubamoylmethyl is preferably used.
- the Q 7, 4-hydroxybenzyl, force Rubamoirumechiru, 3-pyridylmethyl and the like are preferably used, in particular, such as 4-arsenide Dorokishibenji Le is preferably used.
- benzyl, 4-monopyridylmethyl, 2-naphthylmethyl, 3-indolemethyl, hydroxymethyl, cyclohexylmethyl, sec-butyl, 1-hydroxyethyl and the like are preferably used.
- Monopyridylmethyl, 3-indolemethyl, sec-butyl and the like are preferably used.
- the Q 9, such as force Rubamoirumechiru are preferably used.
- Q 1 Q is preferably 4-hydroxybenzyl, 3-indolemethyl, methyl, 1-hydroxyethyl, 3-guanidinopropyl, etc., and particularly preferably 3-indolemethyl. Used.
- ⁇ to ⁇ 3 are of the formula C ON (J 13 ) —, — CSN (J 13 ) —, one C (J 14 ) N (J 13 ) —, or one N (J 13 ) CO — (J 13 and J 14 each represent a hydrogen atom or a C alkyl group).
- C E represented by J 1 3 and J 14 -
- the J 14, a hydrogen atom is preferable.
- Y 1 is preferably a group represented by the formula —CONH— or —CH 2 NH—.
- Y 2 a group represented by the formula (1) CONH— or —CH 2 NH_ is preferable.
- Y 3 is preferably a group represented by the formula (1) CONH— or the like.
- J 3 and Q 3 J 4 and Q 4, J 5 and Q 5, J 6 and Q 6, J 7 and Q 7, J 8 and Q 8 ⁇ , J 9 and Q 9, J 1 0 and Q 1 0 , may form a ring by J 1 1 and Q 1 1 J 1 2 and Q 12 is attached.
- J 2 and Q 3 Y 1 and Q 4, Y 2 and Q 5, Y 3 and Q 6, J 2 and Q 7, Y 2 and Q 8, Y 3 and Q 9, J 2 and Q 1 (), Y 3 and Q 11 J 2 and Q 12 combine to form a ring May be formed.
- J 2 and Q 3 , J 2 and Q 7 , J 2 and Q 1 () , and J 2 and Q 12 combine to form a ring, J 2 — C (J 3 ) (Q 3 ), J 2 -C (J 7 ) (Q 7 ), J 2 -C (J 1 °) (Q 1 °), J 2 -C (J 12 ) (Q 12 ), for example, pyrrolidine, Form lysine, thiazolidine.
- Y 1 and Q 4 Y 2 and Q 5, Y 3 and Q 6, Y 2 and Q 8, Y 3 and Q 9, if Y 3 and Q 1 1 are combined to form a ring
- Y 1 C ( J 4) Q 4
- Y 2 C (J 5) Q 5
- Y 3 C (J 6) Q "
- Y 2 C (J 8) Q 8
- Y 3 C (J 9) Q 9
- Y 3 C (J 11 ) (Q 11 ) form, for example, pyrrolidine 12-force ruponyl, piperidine-2-force ruponyl, and thiazolidine 14-force rutile.
- Equation J 1 — J 2 -C (J 3 ) (Q 3 ) Y 1 C (J 4 ) (Q 4 ) Y 2 C (J 5 ) (Q 5 ) Y 3 C (J 6 ) (Q 6 ) C ( Z 1 °)
- a group represented by one for example,
- Tyr Asn Trp (For) Asn-, D ⁇ Tyr Asn D-Trp Asn-, D-Tyr Asn Ala Asn-, D-Tyr Asn Ser Asn-, D-Tyr Asn Cha Asn-, D-Tyr Asn Thr Asn- , D-Tyr Asn lie Asn-, D-Tyr Gin Trp Asn-, D-Tyr Thr Trp Asn-, D-Tyr Asn Val Asn-, D-Tyr D-Asn Trp Asn-, D-Tyr D-Asn D -Trp Asn-, D-Tyr Asn Phe Asn-, D-Tyr Asn Nal (1) Asn-, D-Tyr Asn Nal (2) Asn-, D-Tyr Asn Phe (2C1) Asn-, D-Tyr Asn Phe (3C1) Asn-, D-Tyr Asn Phe (4C1) Asn-, D-
- Equation “—” C (J 1 °) (Q 10 ) Y 3 C (J 1 M (Q 1 1 ) C (
- D-Glucronyl Asn- and the like are preferred.
- a hydrogen atom and the like are preferable.
- metastin derivative (I) of the present invention all compounds in which the groups of the respective symbols described above are arbitrarily combined are preferably used. It is.
- Compound No. 224 des (1) - [ D-Tyr2, D-Trp3, Arg (Me) 9] MSIO D - Tyr- D- Trp- Asn-Ser- Phe_Gly- Leu- Arg (Me) -Phe-NH 2
- Compound number 225 des (1)-[D-Asn2, D-Trp3, Arg (Me) 9] MSIO D-Asn-D-Trp-Asn-Ser-P e-Gly-Leu-Arg (Me) -Phe -NH 2
- Compound number 256 des (1)-[D-Pya (3) 2, Phe3, AzaGly7, Arg (Me) 91MS10 D-Pya (3) -P e-Asn-Ser-P e-AzaGly-Leu-Arg ( Me) -Phe-NH 2
- Compound number 265 des (1-3) -Indole-3-carbonyl- [AzaGly7, Arg (Me) 91MS10 Indole-3-carbonyl-Asn-Ser-Phe-AzaGly-Leu-Arg (Me) -Phe-NH 2
- Compound number 266 des (1-3) -Indole-3-acetyl- [AzaGly7, Arg (Me) 9] MS10 Indol-3-acetyl-Asn-Ser-Phe-AzaGly-Leu-Arg (Me) -Phe- NH 2
- Compound number 315 des (1)-[D-Asn2, Ca3, AzaGly7, Arg (Me) 9] MS10, D-Asn-Cha-Asn-Ser-Pe-AzaGly-Leu-Arg (Me) -Phe -NH 2
- the metastin derivative (I) of the present invention comprises the first to fifth (compound number 1), the second to fifth, the third to fifth, and the fourth amino acid sequence of the amino acid sequence represented by SEQ ID NO: 1. ⁇ 54th, 5th-54th, 6th-54th, 7th-54th, 8th-54th, 9th-54th, 10th-54th, No.
- FIG. 1 shows the evaluation of the migration inhibitory activity of Compound 322, Compound 305, Compound 303, Compound 286, Compound 232, and Compound 141 using I10T7T175-expressing CH0 cells.
- FBS—on the horizontal axis is without FBS
- FBS + is with FBS
- 3 2 2 is with compound 3 2
- 3 0 5 is with compound 3 0 5
- 3 0 3 is compound 3 0 3 when adding 2 286 when adding compound 2 86, 2 3 when adding compound 2 32, 1 4 1 when adding compound 14 1
- (1-5 4) is metastin (1—54) shows the case of addition
- (45—54) shows the case of metastin 45—54.
- FIG. 2 shows the evaluation of the tumor growth inhibitory activity of compound 322 and Metastin (1-54) using human colon cancer-derived cell line SW620 tumor-bearing mice. Values represent (average) soil (standard error). ⁇ is V ehic 1 e (distilled water), ⁇ is compound 3 2 (0.1 m), parable is compound 3 2 (1 mM), ⁇ is Met as Un (Metastin 1-54). The result at the time of addition is shown.
- the horizontal axis shows the number of days after administration You. The bar on the horizontal axis indicates the administration period.
- the vertical axis shows the tumor volume (mm 3 ).
- FIG. 3 shows the evaluation of the tumor growth inhibitory activity of compound 305 and Metastin (1-54) using human colon cancer-derived cell line SW620 tumor-bearing mouse. The value indicates (mean value) (standard error).
- ⁇ means V ehic 1 e (distilled water)
- ⁇ means compound 30 5 (0. ImM)
- ⁇ means compound 305 (1 mM)
- Meta means Metastin (Metastin 1-5.4). The results are shown.
- the horizontal axis indicates the number of days after administration. The par on the horizontal axis indicates the administration period.
- the vertical axis indicates the tumor volume (mm 3 ).
- FIG. 4 shows the results of examining the change in the concentration of darcose in blood when metastin was intravenously administered to a rat under anesthesia.
- (1-1) is a group administered with physiological saline
- (1-1) is a group administered with 17 nmol / kg of metastin
- (- ⁇ -) is a group administered with 80 nmol / kg of metastin
- (- ⁇ 1) Represents the blood glucose concentration of the metastin 170 nmol / kg administration group.
- FIG. 5 shows the results of examining the change in blood dalcagon concentration when metastin was intravenously administered to an anesthetized rat.
- (1.1) indicates the blood glucagon concentration in the physiological saline administration group
- (1) indicates the metastin 80 nmol / kg administration group.
- FIG. 6 shows the results of examining the change in blood insulin concentration when metastin was intravenously administered to a rat under anesthesia.
- (—o—) represents the physiological saline administration group
- (1.1) represents the blood insulin concentration of the metastin 80 nmol / kg administration group.
- Figure 5 shows the results of examining the change in blood corticosterone concentration when metastin was intravenously administered to a rat under anesthesia.
- (1.1) represents the blood corticosterone concentration of the physiological saline administration group
- (1.1) represents the metastin 80 nniol / kg administration group.
- FIG. 8 shows the results of examining changes in blood thyroid hormone (T3) concentration when metastin was intravenously administered to a rat under anesthesia.
- T3 blood thyroid hormone
- (—o—) represents the physiological saline administration group
- (1.1) represents the blood thyroid hormone (T3) concentration in the metastin 80 nmol / kg administration group.
- FIG. 9 shows the results of examining the fluctuations in the blood concentration of dalcose when metastin was intravenously administered to a rat under anesthesia.
- (1.1) represents the blood glucose concentration of the physiological saline administration group
- (1.1) represents the blood glucose concentration of the metastin 80 nmol / kg administration group.
- FIG. 10 shows the results of examining the change in blood glucose concentration when a metastin derivative was intravenously administered to a rat under anesthesia.
- (1-1) is the saline saline administration group
- (1-1) is the KiSSl-305 80 nmol / kg administration group
- (1-A) is the KiSSl-322 80 nmol / kg administration group.
- Represents blood glucose concentration. Values represent the standard deviation of the mean (mean ⁇ SE) (n 5). * Indicates that the P value is 0.05 or less as compared with the physiological saline administration group. ** indicates that the P value is 0.01 or less as compared with the physiological saline administration group.
- FIG. 1 is the saline saline administration group
- (1-1) is the KiSSl-305 80 nmol / kg administration group
- (1-A) is the KiSSl-322 80 nmol / kg administration group.
- FIG. 11 shows the results of examining changes in blood glucagon concentration when metastin was intravenously administered to a rat under anesthesia.
- (1o—) is the saline administration group
- (1 ⁇ 1) is KiSSl-305 (compound 300), 80 nmol / kg administration group
- (1-1) is KiSS U322 (compound).
- 32 2) Shows the blood glucagon concentration in the 80 nmol / kg administration group.
- Means P value of 0.05 compared to saline administration group Indicates that:
- FIG. 12 is a diagram showing the concentration of estradiol contained in rat plasma.
- the vertical axis indicates the estradiol concentration
- the horizontal axis indicates the drug administration group.
- FIG. 13 is a graph showing the concentration of progesterone contained in rat plasma.
- the vertical axis shows the estradiol concentration
- the horizontal axis shows the drug administration group.
- FIG. 14 is a graph showing changes in the FSH concentration in immature rat blood due to metastin administration.
- FIG. 15 is a graph showing the change in LH concentration in immature rat blood due to metastin administration.
- FIG. 16 is a graph showing changes in progesterone concentration in immature rat blood due to metastin administration.
- FIG. 17 is a graph showing the change in rat blood FSH concentration due to metastin administration.
- FIG. 18 is a graph showing changes in LH concentration in rat blood due to metastin administration.
- FIG. 19 is a graph showing the change in rat testosterone concentration caused by metastin administration.
- FIG. 20 is a diagram showing the number of ovulations per rat in each administration group measured in Test Example 13.
- ⁇ indicates the value for each rat, and indicates the average value in each group.
- FIG. 21 is a diagram showing the blood estradiol concentration in each administration group measured in Test Example 13.
- ⁇ indicates the value for each rat, and indicates the average value in each group.
- FIG. 22 is a diagram showing the blood progesterone concentration in each administration group measured in Test Example 13.
- ⁇ indicates the value for each rat
- 1 indicates the average value in each group.
- SEQ ID NO: 16 C-terminal is amidated
- the metastin derivative (I) of the present invention can be produced according to a peptide synthesis method known per se.
- a method for synthesizing a peptide for example, any of solid phase synthesis and liquid phase synthesis may be used. That is, the target peptide is produced by condensing a partial peptide or amino acid capable of constituting the peptide of the present invention with the remaining portion, and if the product has a protective group, removing the protective group to produce the desired peptide. be able to. Examples of known condensation methods and methods for removing protecting groups include the methods described in the following (1) to (5).
- the peptide of the present invention can be purified and isolated.
- the peptide obtained by the above method is a free form, it can be converted to an appropriate salt by a known method, and conversely, when the peptide is obtained as a salt, it can be converted to a free form by a known method. it can.
- various activating reagents that can be used for peptide synthesis can be used, and in particular, trisphosphonium salts, tetramethylperonium salts, carposimids and the like are preferable.
- Trisphosphonium salts include benzotriazole-1-yloxytris (pyrrolidino) phosphohexafluorophosphate (PyB0P), promotris (pyrrolidino) phosphonium hexafluorophosphate (PyBroP), 7-azaza Benzotriazole-1_yloxytris (pyrrolidino) phosphoniumhexafluo Mouth phosphate (PyAOP), tetramethylmethyl nitrate 2_ (1H-benzotriazole-1-yl) -1,1,3,3hexafluoro Phosphate (HBTU), 2- (7-azabenzotriazole-tril)-1, 1, 3, 3 hexafluorophosphate (HATU), 2--(1H-benzotriazole-tril)- 1,1,3,3-tetramethylperonium tetrafluoroborate (TBTU), 2- (5-norporene-2,3-dicaroxime )-1,1,
- a racemization inhibitor eg, HONB, HOBt, HOAt, HOOBt, etc.
- the solvent used for the condensation can be appropriately selected from solvents known to be usable for the peptide condensation reaction.
- anhydrous or water-containing acid amides such as N, N-dimethylformamide, N, N-dimethylacetamide and N-methylpyrrolidone; halogenated hydrocarbons such as methylene chloride and chloroform; Alcohols such as roethanol and phenol; sulfoxides such as dimethyl sulfoxide; tertiary amines such as pyridine; ethers such as dioxane and tetrahydrofuran; nitriles such as acetonitrile and propionitrile; methyl acetate; ethyl acetate; Esters or an appropriate mixture thereof are used.
- the reaction temperature is It is appropriately selected from a range known to be usable for peptide bond formation reaction, and is usually selected from a range of about 120 ° C. to 50.
- the activated amino acid derivative is usually used in a 1.5 to 6-fold excess.
- the condensation is insufficient, sufficient condensation can be performed by repeating the condensation reaction without removing the protecting group. .
- the unreacted amino acid can be acylated using acetic anhydride or acetylimidazole or the like so that the subsequent reaction is not affected.
- Examples of the protecting group for the amino group of the starting amino acid include Z, Bo tert-pentyloxycarbonyl, isopolnyloxycarponyl, 4-methoxybenzyloxycarpoyl, CutZ, Br-Z, and adamantyloxy.
- Examples include carbonyl, trifluoroacetyl, phthaloyl, formyl, 2-2 trophenylsulfenyl, diphenylphosphinothioyl, and Fmoc.
- Rupokishiru group for example C i-6 alkyl group noted above as R, C 3 _ 8 cycloalkyl group, other C 7 _ 1 4 7 Raruki group, Ariru, 2 Adamanchiru, 4 twelve Benzyl, 4-methoxybenzyl, 4-cyclobenzyl, phenacyl group and benzyloxycarbonyl hydrazide, tert-butoxycarbonyl hydrazide, trityl hydrazide and the like.
- the hydroxyl groups of serine and threonine can be protected, for example, by esterification or etherification.
- the esterification Suitable as a group lower, e.g. Asechiru group (C 2 - 4) Arukanoiru group, and a group derived from an organic acid, such as Aroiru groups such Benzoi Le group.
- groups suitable for etherification include a benzyl group, a tetrahydrobiranyl group, a tert-butyl group, and a trityl group (Trt).
- Examples of the phenolic hydroxyl-protecting group of tyrosine include none, 2,6-dichlorobenzyl, 2-nitrobenzyl, .Br-Z, tert-butyl and the like.
- Examples of the imidazole protecting group for histidine include Tos, 4-methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr), DNP, Bom, Bum, Boc, Trt, and Fmoc.
- Protecting groups for the guanidino group of arginine include Tos, Z, 4-methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr), p-methoxybenzenes fulphonyl (MBS), 2, 2, 5, 7 , 8 -Pentamethylcuman-6-sulfonyl (Pmc), mesitylene-2-sulfonyl (Mts), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbi), Boc, Z, N0 2, such as the Ru and the like.
- Examples of the protecting group for the side chain amino group of lysine include Z, C 1-Z, trifluoroacetyl, Boc, Fmoc, Trt, Mtr, 4,4-dimethyl-2,6-dioxocyclohexylideneyl (Dde) and the like.
- indolyl protecting group of tributofan examples include formyl (For), Z, Boc, Mts, Mtr and the like.
- Protecting groups for asparagine and glutamine include Trt, xanthyl (Xan), 4,4'-dimethoxybenzhydryl (Mbh), and 2,4,6-trimethoxybenzyl (Tmob).
- activated raw propyloxyl groups include, for example, corresponding acid anhydrides, azides, and activated esters [alcohols (eg, pentachlorophenol, 2,4,5-trichlorophenol, 2,4- Dinitrophenol, cyanomethyl alcohol, paranitrophenol, H0NB, N-hydroxysuccinimide, 1-hydroxybenzotriazole (HOBt), 11-hydroxy-7-azabenzotriazole (HOAt)
- the activated amino group of the raw material includes, for example, a corresponding phosphite amide.
- Methods for removing (eliminating) protecting groups include catalytic reduction in the presence of a catalyst such as Pd black or Pd carbon in a stream of hydrogen, or anhydrous hydrogen fluoride, methanesulfonic acid, or trifluoromethane.
- a catalyst such as Pd black or Pd carbon in a stream of hydrogen, or anhydrous hydrogen fluoride, methanesulfonic acid, or trifluoromethane.
- TMSBr trimesylsilane bromide
- the elimination reaction by the above acid treatment is generally carried out at a temperature of 120 ° C ( ⁇ 40 ° C) .
- cation capture such as anisol, phenol, thioanisole, methacrylol, paracresol, etc. It is effective to add dimethyl sulfide, 1,4-butanedithiol, 1,2-ethanedithiol, etc.
- the 2,4-dinitrophenyl group used as an imidazole protecting group of histidine is thiophenol.
- the formyl group which is removed by treatment and used as an indole protecting group for tributofan is not only deprotected by acid treatment in the presence of 1,2-ethanedithiol and 1,4-butanedithiol as described above, but also by dilute sodium hydroxide and dilute sodium. It is also removed by alkali treatment with ammonia or the like.
- Protection and protection of functional groups that should not be involved in the reaction of the raw materials, elimination of the protective groups, activation of the functional groups involved in the reaction, and the like can be appropriately selected from known protective groups or known means.
- the amide form of the peptide can be obtained by solid-phase synthesis using an amide form synthesis resin, or by amidating a single lipoxyl group of the terminal amino acid of the propyloxyl group, and then adding a peptide chain to the amino group side. After extending to the desired chain length, the peptide obtained by removing only the N! -Terminal Q! -Amino protecting group and the peptide obtained by removing only the C-terminal protecting group of the carboxyl group (or Amino acid) and both peptides are condensed in a mixed solvent as described above. Details of the condensation reaction are the same as described above.
- the metastin derivative (I) of the present invention is a constitutive When present as isomers (configuration isomers), diastereomers, conformers, etc., each can be isolated by the above-mentioned separation and purification means, if desired. When the compound of the present invention is in a racemic form, it can be separated into an S-form and an R-form by ordinary optical resolution means. When the metastin derivative (I) of the present invention has a stereoisomer, The present invention also includes the case where the isomer is used alone and the case of a mixture thereof.
- the metastin derivative (I) of the present invention may be a hydrate or a non-hydrate.
- Metastin derivative (I) of the present invention an isotope (eg, 3 H, 14 C, 3 5 S) may be labeled with the like.
- the left end is the N-terminal (amino end) and the right end is the C-terminal (capilloxy terminal) according to the convention of the notation of the peptide.
- the C-terminus of the peptide is an amide (—CONH 2 ), a carbonyl group (one COOH), a carboxylate (_CO ⁇ —), an alkylamide (—CONHR) or an ester (one COOR). Although it may be present, an amide (one CONH 2 ) is particularly preferred.
- R of the ester or alkylamino de, for example methyl, Echiru, n- propyl, C _ 6 alkyl groups such as isopropyl or n- butyl Le, cyclopentyl, C 3 _ 8 cycloalkyl group such as cyclohexyl, phenyl, Q !
- Ararukiru groups such as flying one Nafuchiru C ⁇ alkyl such as C alkyl or a- naphthylmethyl - 1 2 ⁇ Li one group, benzyl, phenethyl, phenyl, such as benzhydryl - C 6, such as naphthyl
- a bivaloyloxymethyl group commonly used as an oral ester and the like can be mentioned.
- Examples of the salt of the metastin derivative (I) of the present invention include metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, and salts with basic or acidic amino acids. Is mentioned.
- Preferable examples of the metal salt include an alkali metal salt such as a sodium salt and a potassium salt; a calcium salt; Alkaline earth metal salts such as magnesium salts and barium salts; aluminum salts and the like.
- Preferred examples of the salt with an organic base include, for example, trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine.
- salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like.
- Suitable examples of salts with organic acids include, for example, formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, Salts with benzenesulfonic acid, P-toluenesulfonic acid and the like can be mentioned.
- Preferred examples of the salt with a basic amino acid include, for example, salts with arginine, lysine, orditin and the like.
- Preferred examples of the salt with an acidic amino acid are-, for example, aspartic acid, glutamic acid, etc. Salts.
- salts are preferred.
- the compound when it has an acid functional group, it may be an alkali metal salt (eg, sodium salt, potassium salt, etc.), an alkaline earth metal salt (eg, calcium salt, magnesium salt, barium salt, etc.).
- alkali metal salt eg, sodium salt, potassium salt, etc.
- alkaline earth metal salt eg, calcium salt, magnesium salt, barium salt, etc.
- an inorganic salt, an ammonium salt, or the like has a basic functional group in the compound, for example, a salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, or acetic acid or phthalic acid
- an inorganic acid such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, or acetic acid or phthalic acid
- organic acids such as fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid and p-toluenesulfonic acid.
- the prodrug of the metastin derivative (I) of the present invention or a salt thereof (hereinafter, abbreviated as the metastin derivative (I) of the present invention) can be obtained by a reaction with an enzyme, stomach acid, or the like under in vivo physiological conditions.
- the metastin derivative which is converted to the metastin derivative (I) that is, the metastin derivative which is enzymatically oxidized, reduced, hydrolyzed, etc. to be converted to the metastin derivative of the present invention, the metastin derivative of the present invention which is hydrolyzed by gastric acid, etc.
- Examples of the prodrug of the metastin derivative (I) of the present invention include a metastin derivative in which the amino group of the metastin derivative (I) of the present invention is acylated, alkylated, or phosphorylated (for example, a metastin derivative (I) of the present invention).
- metastin derivative in which the hydroxyl group of the metastin derivative (I) of the present invention is acylated, alkylated, phosphorylated or borated (for example, a metastin derivative of the present invention).
- the hydroxyl group of the derivative (I) is acetylated, palmitoylated, propionylated, and vivalo , Succinylation, fumarylation, alanylation, dimethylaminomethylcarboylated metastin derivative, etc.); a metastin derivative in which the carboxy group of the metastin derivative (I) of the present invention is esterified or amidated (For example, when the dextrin group of the metastin derivative (I) of the present invention is ethylesterified, phenylesterified, ethoxypropylesterified, dimethylaminomethylesterified, bivaloyoxymethylesterified, ethoxycarponyloxethyl) Esterification, phthalidyl esterification, (5-methyl-2-oxo-1, 3-dioxolen-4-yl) methyl esterification, cyclohexyloxycarponylethyl esterification, methyl
- the prodrug of the metastin derivative (I) of the present invention can be prepared under physiological conditions as described in Hirokawa Shoten, 1990, “Development of Pharmaceuticals,” Vol. 7, Molecular Design, pp. 163-198. May be changed to the metastin derivative (I) of the present invention.
- the metastin derivative (I) of the present invention or a prodrug of a salt thereof (hereinafter sometimes abbreviated as the compound of the present invention) has a cancer metastasis inhibitory activity or a cancer growth inhibitory activity.
- a cancer metastasis inhibitory activity or a cancer growth inhibitory activity.
- Useful as medicines for the prevention and treatment of any cancer eg, lung, stomach, liver, knee, colon, rectum, colon, prostate, ovarian, cervical, breast, etc. is there.
- the compound of the present invention has a knee function-regulating action, it is useful as a Teng function-regulating agent, as a therapeutic or prophylactic agent for various knee diseases (eg, acute or chronic inflammation, Teng cancer, etc.). .
- the compound of the present invention has a placental function regulating action, as a placental function regulating agent, for example, choriocarcinoma, hydatidiform mole, invasive mole, miscarriage, fetal growth dysfunction, abnormal glucose metabolism, abnormal lipid metabolism or It is useful as a drug such as an agent for preventing or treating labor induction.
- a placental function regulating agent for example, choriocarcinoma, hydatidiform mole, invasive mole, miscarriage, fetal growth dysfunction, abnormal glucose metabolism, abnormal lipid metabolism or It is useful as a drug such as an agent for preventing or treating labor induction.
- the compound of the present invention has a blood sugar increasing action, a tunnel glucagon secretion promoting action, and a urine production promoting action
- it can be used as a blood glucose increasing agent, a Teng glucagon secretion promoting agent, a urine production promoting agent such as obesity, Lipidemia, type 2 diabetes, hypoglycemia, hypertension, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, edema, dysuria, insulin resistance, unstable diabetes, lipoatrophy, insulin allergy, insulinoma, artery
- a medicament such as an agent for preventing or treating sclerosis, thrombotic disease or lipotoxicity.
- the compounds of the present invention may have a gonadotropin (eg, FSH, LH, etc.) secretion promoting action, a sex hormone (eg, androgen (eg, testosterone, androstenedione, etc.), an estrogen (eg, estradiol, estrone).
- a gonadotropin eg, FSH, LH, etc.
- a sex hormone eg, androgen (eg, testosterone, androstenedione, etc.)
- an estrogen eg, estradiol, estrone
- gonad function improving agent e.g., ovulation induction or promotion agent
- gonadotropin secretion Accelerator or sex hormone secretagogue hormone-dependent cancer (eg, prostate cancer, breast cancer, etc.), infertility (eg, irregular menstruation, dysmenorrhea, amenorrhea, weight loss, amenorrhea, secondary amenorrhea Menstruation, anovulation, ovarian hypofunction, hypogonadism, spermatogenesis disorder, hypogonadism (eg, impotence) Genital atrophy, testicular atrophy, testicular function disorder, azoospermia, etc. low androgenic hypertriglyceridemia], endometriosis, be used as a prophylactic or therapeutic agent for uterine fibroids it can.
- hormone-dependent cancer eg, prostate cancer, breast cancer, etc.
- infertility eg, irregular menstruation, dysmenorrhea, am
- metastin derivative of the present invention or a salt thereof or a prodrug thereof is useful as an agent for preventing or treating Alzheimer's disease, mild cognitive impairment and the like.
- the compounds of the present invention have better blood stability than natural metastin, for example, metastin 54 (1-5) ⁇ metastin 10 (45-54).
- the medicament containing the compound of the present invention has low toxicity, and according to a method known per se which is generally used in a method for producing a pharmaceutical preparation, the compound of the present invention can be used as it is or a pharmacologically acceptable carrier.
- Pharmaceutical preparations such as tablets (including sugar-coated tablets, film-coated tablets), powders, granules, capsules, (including soft capsules), liquids, injections, suppositories, sustained-release tablets, etc. Can be safely administered orally or parenterally (eg, topically, rectally, intravenously, etc.).
- the content of the compound of the present invention in the preparation of the present invention is about 0.01 to about 100% by weight of the whole preparation.
- the dose of the compound of the present invention varies depending on the administration subject, target organ, symptoms, administration method, and the like. However, in the case of oral administration, it is generally one dose to a cancer patient (assuming a body weight of 60 kg). About 0.1 to 100 mg, preferably about 1.0 to 50 mg, more preferably about 1.0 to 20 mg per day. In the case of parenteral administration, the single dose varies depending on the administration target, target organ, symptoms, administration method, etc. For example, in the case of injection, cancer patients (typically 60 kg body weight) ), About 0.01 to 30 mg per day, preferably about 0.1 to 20 mg, more preferably about 0.1 to 1 mg per day. Is convenient. In the case of other animals, the dose can be administered in terms of weight per 60 kg.
- Examples of the pharmacologically acceptable carrier that may be used in the production of the medicament of the present invention include various organic or inorganic carrier substances commonly used as pharmaceutical materials, for example, excipients in solid formulations, Lubricants, binders and disintegrants, are And liquid preparations such as solvents, solubilizers, suspending agents, tonicity agents, buffers, and soothing agents. Further, if necessary, additives such as ordinary preservatives, antioxidants, coloring agents, sweeteners, adsorbents, wetting agents and the like can be used in appropriate amounts.
- Excipients include, for example, lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light caffeic anhydride and the like.
- examples of the lubricant include magnesium stearate, stearic acid potassium, talc, colloid silica and the like.
- binder examples include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, sucrose, gelatin, methylcellulose, and sodium carboxymethylcellulose.
- disintegrant examples include starch, carboxymethylcellulose, calcium propyloxymethylcellulose, carboxymethyl starch sodium, L-hydroxypropyl cellulose and the like.
- Solvents include, for example, water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, olive oil and the like.
- Dissolution aids include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate. , Ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
- suspending agent examples include surfactants such as stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate; for example, polyvinyl alcohol, polyvinyl Pyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl And hydrophilic polymers such as cellulose.
- surfactants such as stearyl triethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate
- polyvinyl alcohol polyvinyl Pyrrolidone
- sodium carboxymethylcellulose methylcellulose
- hydroxymethylcellulose hydroxyethylcellulose
- hydroxypropyl hydroxypropyl
- tonicity agent examples include glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol and the like.
- buffers such as phosphate, acetate, carbonate, and citrate.
- Examples of the soothing agent include benzyl alcohol and the like.
- preservatives include parahydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- antioxidant examples include sulfite, ascorbic acid, ⁇ -tocopherol and the like.
- the compound of the present invention can be used in combination with a drug other than the compound of the present invention.
- Drugs that can be used in combination with the compound of the present invention include, for example, chemotherapeutic agents for treating cancer, hormonal therapeutic agents, and immunotherapeutic agents (hereinafter, concomitant drugs).
- concomitant drugs include, for example, chemotherapeutic agents for treating cancer, hormonal therapeutic agents, and immunotherapeutic agents (hereinafter, concomitant drugs).
- concomitant drugs include, for example, chemotherapeutic agents for treating cancer, hormonal therapeutic agents, and immunotherapeutic agents.
- chemotherapeutic agent examples include an alkylating agent, an antimetabolite, an anticancer antibiotic, and a plant-derived anticancer agent.
- alkylating agent examples include nitrogen mustard, nitrodiene chloride mustoxide, chloroxide, chlorambutyl, cyclophosphamide, diphosphamid, chiotepa, carbocon, improsulfan tosylate, busulfan, and hydrochloric acid.
- antimetabolites include, for example, mercaptopurine, 6-mercaptopurine liposide, thioinosine, methotrexate, enosinobin, shinorapin, shinorabinokfosfuart, ancitabine hydrochloride, 5-FU Drugs (e.g., Fluorouracil, Tegafur, UFT, Doxyfluridine, Carmofur, Garosibin, Emitefur, etc.), Aminopterin, Leukoporin Calcium, Tabloid, Butsin, Forinite Calcium, Lepofluorinated Calcium, Cladribine, Emitefin , Fludarabine, gemushibin, hydroxycarbamide, pentosbin, pyrithrexime, idoxyperidine, mitguazone, thiazofurin, ambamustine.
- 5-FU Drugs e.g., Fluorouracil, Tegafur, UFT, Doxyfluridine, Carmofur
- anticancer antibiotics include actinomycin D, actinonomycin C, mitomycin C, chromomycin A3, bleomycin hydrochloride, bleomycin sulfate, bepromycin sulfate, daunorubicin hydrochloride, doxorubicin hydrochloride, aclarubicin hydrochloride, Examples include pirarubicin hydrochloride, epilubicin hydrochloride, neocarzinostin, mythramycin, sarcomycin, carcinophylline, mitotane, sorbicin hydrochloride, mitoxantrone hydrochloride, idarubicin hydrochloride, and the like.
- plant-derived anticancer agent examples include etoposide, etoposide phosphate, vinblastine sulfate, vincristine sulfate, vindesine sulfate, teniposide, paclitaxel, docetaxel, vinorelbine and the like.
- hormone therapeutic agent examples include, for example, phosphestrol, getylstilbestrol, chlorotrianiserin, medroxyprogesterone acetate, megestrol acetate, chlormadinone acetate, cyproterone acetate, danazol, arylestrenorol, gestrestrinone, mepartrisine.
- Raloxifene, olmelokifene, repolmeloxifene, anti-estrogen eg, moxifen citrate, toremifene quenate Pills, pill preparations, mepithiostan, testloractone, aminoglutethimid, LH-RHagonist (eg, goserelin acetate, pserelin, luproleline, etc.), droloxifene, epitiose, sulphonate estrone radio , Aroma inhibitors, (eg, fadrozole hydrochloride, anastrozole, letrozole, exemestane, porozol, formestane, etc.), antiandrogens (eg, flutamide, bicarmine, Mide, 5-reductase inhibitors (eg, finasteride, everisteride, etc.), corticosteroids (eg, dexamethasone, prednisolone, ves
- immunotherapeutic agent examples include, for example, picibanil, krestin, schizophyllan, lentinan, ubenimex, interphenin, interleukin, macrophage colony stimulating factor, granulocyte colony stimulating factor, erythropoietin, Lymphotoxin, BCG vaccine, corynepacterium pulp, revamisol, polysaccharide K, procodazole and the like.
- the drug used in combination with the compound of the present invention can be selected according to the patient's symptoms (mild, severe, etc.)
- the treatment period can be set longer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/540,494 US20060241051A1 (en) | 2002-12-26 | 2003-12-26 | Metastin derivatives and use thereof |
EP03768337.2A EP1577323B1 (en) | 2002-12-26 | 2003-12-26 | Metastin derivative and use thereof |
AU2003292696A AU2003292696A1 (en) | 2002-12-26 | 2003-12-26 | Metastin derivative and use thereof |
CA002511858A CA2511858A1 (en) | 2002-12-26 | 2003-12-26 | Metastin derivative and use thereof |
US12/455,563 US20090318365A1 (en) | 2002-12-26 | 2009-06-02 | Metastin derivatives and use thereof |
US13/135,230 US8361968B2 (en) | 2002-12-26 | 2011-06-29 | Metastin derivatives and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-377179 | 2002-12-26 | ||
JP2002377179 | 2002-12-26 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/540,494 A-371-Of-International US20060241051A1 (en) | 2002-12-26 | 2003-12-26 | Metastin derivatives and use thereof |
US12/455,563 Continuation US20090318365A1 (en) | 2002-12-26 | 2009-06-02 | Metastin derivatives and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004063221A1 true WO2004063221A1 (ja) | 2004-07-29 |
Family
ID=32708287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/016978 WO2004063221A1 (ja) | 2002-12-26 | 2003-12-26 | メタスチン誘導体およびその用途 |
Country Status (7)
Country | Link |
---|---|
US (3) | US20060241051A1 (ja) |
EP (1) | EP1577323B1 (ja) |
KR (1) | KR20050090420A (ja) |
CN (1) | CN1761680A (ja) |
AU (1) | AU2003292696A1 (ja) |
CA (1) | CA2511858A1 (ja) |
WO (1) | WO2004063221A1 (ja) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004060264A2 (en) * | 2003-01-06 | 2004-07-22 | Takeda Pharmaceutical Company Limited | Metastin derivatives and their use |
WO2006001499A2 (en) * | 2004-06-25 | 2006-01-05 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
EP1750513A2 (en) * | 2004-04-23 | 2007-02-14 | Applied Research Systems ARS Holding N.V. | Use of gpcr54 ligands for the treatment of infertility |
WO2008050897A1 (en) | 2006-10-25 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
WO2009131191A1 (ja) | 2008-04-24 | 2009-10-29 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
WO2010013762A1 (ja) | 2008-07-30 | 2010-02-04 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
WO2010076896A1 (en) | 2008-12-29 | 2010-07-08 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
US7754220B2 (en) | 2003-03-12 | 2010-07-13 | Takeda Pharmaceutical Company Limited | Methods of inhibiting secretion of follicle-stimulating hormone and testosterone |
US7960348B2 (en) | 2005-12-22 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US8361968B2 (en) | 2002-12-26 | 2013-01-29 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
WO2013017631A1 (en) | 2011-08-04 | 2013-02-07 | Msd Oss B.V. | Kisspeptide-pentasaccharide conjugates |
US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US8716228B2 (en) | 2009-05-27 | 2014-05-06 | Yeda Research And Development Co. Ltd. | GPR54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200805393B (en) * | 2005-12-22 | 2009-12-30 | Takeda Pharmaceutical | Metastin derivatives and use thereof |
US20090099334A1 (en) * | 2005-12-22 | 2009-04-16 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
JP5279021B2 (ja) * | 2006-04-26 | 2013-09-04 | 国立大学法人京都大学 | Gpr54アゴニスト活性を有する新規化合物 |
RU2454425C2 (ru) * | 2006-10-25 | 2012-06-27 | Такеда Фармасьютикал Компани Лимитед | Производные метастина и их применение |
ZA200902452B (en) * | 2006-10-25 | 2010-07-28 | Takeda Pharmaceutical | Metastin derivatives and use thereof |
US8110639B2 (en) * | 2006-11-17 | 2012-02-07 | Solvay Advanced Polymers, L.L.C. | Transparent and flame retardant polysulfone compositions |
GB0719592D0 (en) * | 2007-10-08 | 2007-11-14 | Medical Res Council | Compound, use and method |
JP5700641B2 (ja) * | 2008-04-30 | 2015-04-15 | 国立大学法人京都大学 | メタスチン誘導体およびその用途 |
MX2012006441A (es) * | 2009-12-22 | 2012-06-28 | Takeda Pharmaceutical | Formulacion de liberacion sostenida. |
CN104246497B (zh) * | 2012-03-18 | 2017-10-13 | 国立大学法人九州大学 | 疾病样品分析装置、分析系统及分析方法 |
FR3001455B1 (fr) * | 2013-01-31 | 2017-10-06 | Agronomique Inst Nat Rech | Composes agonistes du recepteur kiss1r et leur utilisation pour induire l'ovulation chez les mammiferes |
BR102013008990A2 (pt) * | 2013-04-12 | 2014-12-30 | Ouro Fino Participacoes E Empreendimentos S A | Composições farmacêuticas compreendendo kisspeptina ou seus derivados |
WO2015112703A1 (en) * | 2014-01-22 | 2015-07-30 | The Johns Hopkins University | Compositions and methods for treating diabetes |
US20150302059A1 (en) * | 2014-04-16 | 2015-10-22 | Samsung Electronics Co., Ltd. | Content recommendation apparatus and the method thereof |
US10579652B2 (en) * | 2014-06-17 | 2020-03-03 | Microsoft Technology Licensing, Llc | Learning and using contextual content retrieval rules for query disambiguation |
US11400054B2 (en) * | 2017-06-30 | 2022-08-02 | Industrial Technology Research Institute | Method for treating an autoimmune neurological disease and/or neurodegenerative disease and pharmaceutical formulations for a liquid dosage form and a controlled release dosage form |
CN114334022B (zh) * | 2021-12-31 | 2022-11-18 | 杭州剂泰医药科技有限责任公司 | 一种化合物分子的溶解度预测模型及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000024890A1 (fr) | 1998-10-27 | 2000-05-04 | Takeda Chemical Industries, Ltd. | Nouvellesroteines receptrices couplees aux proteines g, leurs adn et leursigands |
WO2001075104A1 (fr) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Nouvelle proteine, adn codant pour celle-ci, et son procede de production |
WO2002085399A1 (en) | 2001-04-20 | 2002-10-31 | Takeda Chemical Industries, Ltd. | Peptide-containing preparations |
WO2002092829A1 (fr) * | 2001-05-17 | 2002-11-21 | Takeda Chemical Industries, Ltd. | Procede de production d'un peptide |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL74827A (en) | 1984-05-21 | 1989-06-30 | Salk Inst For Biological Studi | Peptides active as gnrh antagonists and pharmaceutical compositions containing them |
MX9100717A (es) | 1990-08-24 | 1992-04-01 | Syntex Inc | Antagonistas de la bradiquinina |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
JPH09169735A (ja) | 1995-10-19 | 1997-06-30 | Takeda Chem Ind Ltd | キノリン誘導体、その製造法および用途 |
WO1997040071A1 (en) | 1996-04-19 | 1997-10-30 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
WO1998039448A2 (en) | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 186 human secreted proteins |
US6528054B1 (en) | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
SK18852001A3 (sk) | 1999-06-28 | 2002-12-03 | Basf Aktiengesellschaft | Použitie látok potláčajúcich LTBR-sprostredkovanú aktiváciu |
US6638906B1 (en) | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
KR20020065510A (ko) | 1999-12-17 | 2002-08-13 | 다케다 야쿠힌 고교 가부시키가이샤 | KiSS-1 펩티드의 제조 방법 |
JP2004526401A (ja) | 2000-03-29 | 2004-09-02 | コリクサ コーポレイション | 肺癌の治療および診断のための組成物および方法 |
US7834141B1 (en) | 2000-03-31 | 2010-11-16 | Theresa Siler-Khodr | Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy |
RU2311920C2 (ru) | 2000-09-20 | 2007-12-10 | Корикса Корпорейшн | Композиции и способы для лечения и диагностики рака легких |
JP2003026601A (ja) | 2000-11-29 | 2003-01-29 | Takeda Chem Ind Ltd | 医薬組成物およびその製造法 |
WO2003027149A1 (fr) | 2001-09-19 | 2003-04-03 | Takeda Chemical Industries, Ltd. | Anticorps et utilisation de ce dernier |
AU2003201854A1 (en) | 2002-01-11 | 2003-07-30 | Takeda Chemical Industries, Ltd. | PROCESS FOR PRODUCING KiSS-1 PEPTIDE |
JP2003300906A (ja) | 2002-04-12 | 2003-10-21 | Daiichi Fine Chemical Co Ltd | がん転移抑制因子の安定化 |
DE60327344D1 (de) | 2002-10-25 | 2009-06-04 | Takeda Pharmaceutical | Gpr54 'knock-out' säugetiere und screening-verfahren, die sie verwenden |
JP4804714B2 (ja) | 2002-12-26 | 2011-11-02 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
US20060241051A1 (en) | 2002-12-26 | 2006-10-26 | Chieko Kitada | Metastin derivatives and use thereof |
US6800611B2 (en) | 2003-01-06 | 2004-10-05 | Takeda Chemical Industries, Ltd. | Metastin derivatives and their use |
KR100595364B1 (ko) | 2003-02-20 | 2006-07-03 | 재단법인 목암생명공학연구소 | Lk8 단백질을 유효성분으로 포함하는 항암제 |
WO2004080479A1 (ja) | 2003-03-12 | 2004-09-23 | Takeda Pharmaceutical Company Limited | 性腺機能改善剤 |
JP2006523573A (ja) | 2003-03-12 | 2006-10-19 | コリンズ・アンド・アイクマン・プロダクツ・コーポレーション | 車両内部構成部材のデカップラを形成する改善された方法 |
EP1464652A1 (en) | 2003-04-02 | 2004-10-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases |
US20050002935A1 (en) | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
WO2004096855A2 (en) | 2003-04-28 | 2004-11-11 | Wyeth | Methods utilising g-protein coupled receptor 54 |
WO2004101747A2 (en) | 2003-05-07 | 2004-11-25 | The General Hospital Corporation | Identification and use of gpr54 and its ligands for reproductive disorders and contraception |
ATE399763T1 (de) | 2003-05-30 | 2008-07-15 | Prozymex As | Proteasehemmer |
DE60336353D1 (de) | 2003-11-03 | 2011-04-21 | Beijing Sunbio Biotech Co Ltd | Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung |
RU2333221C2 (ru) | 2003-11-03 | 2008-09-10 | Бейцзин Санбио Байотек Ко., Лтд. | Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение |
WO2005095973A2 (en) | 2004-03-25 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54) |
BRPI0512397A (pt) | 2004-06-25 | 2008-03-04 | Takeda Pharmaceutical | composto,produto farmacêutico, métodos para suprimir a metástase de cáncer ou o crescimento do cáncer, para prevenir ou tratar uma doença ou condição, para controlar a função placentária, para melhorar a função gonadal, para induzir ou estimular a ovulação, para promover a secreção do hormÈnio gonadotrópico ou promover a secreção do hormÈnio sexual, para suprimir a secreção do hormÈnio gonadotrópico ou suprimir a secreção do hormÈnio sexual, para infra regular hormÈnio gonadrotópico ou hormÈnio sexual, e a proteìna ot7t175 humana, e para realçar a estabilidade no sangue, uso do composto, e, agente para suprimir a secreção do hormÈnio gonadotrópico ou um agente para suprimir a secreção do hormÈnio sexual |
WO2007084211A2 (en) | 2005-11-11 | 2007-07-26 | The General Hospital Corporation | Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception |
TWI386417B (zh) | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
CA2647027A1 (en) | 2006-03-20 | 2007-09-27 | Merck & Co., Inc. | Neuromedin u receptor agonists and uses thereof |
JO3048B1 (ar) | 2006-10-25 | 2016-09-05 | Takeda Pharmaceuticals Co | مشتقات متاستين واستخدامها |
US20100286035A1 (en) * | 2007-10-05 | 2010-11-11 | Takeda Pharmaceutical Company Limited | Neuromedin u derivative |
US20110118172A1 (en) | 2008-04-24 | 2011-05-19 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
WO2010033224A1 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of kiss1 peptides |
-
2003
- 2003-12-26 US US10/540,494 patent/US20060241051A1/en not_active Abandoned
- 2003-12-26 CA CA002511858A patent/CA2511858A1/en not_active Abandoned
- 2003-12-26 AU AU2003292696A patent/AU2003292696A1/en not_active Abandoned
- 2003-12-26 CN CNA200380110012XA patent/CN1761680A/zh active Pending
- 2003-12-26 EP EP03768337.2A patent/EP1577323B1/en not_active Expired - Lifetime
- 2003-12-26 WO PCT/JP2003/016978 patent/WO2004063221A1/ja active Application Filing
- 2003-12-26 KR KR1020057012083A patent/KR20050090420A/ko not_active Application Discontinuation
-
2009
- 2009-06-02 US US12/455,563 patent/US20090318365A1/en not_active Abandoned
-
2011
- 2011-06-29 US US13/135,230 patent/US8361968B2/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000024890A1 (fr) | 1998-10-27 | 2000-05-04 | Takeda Chemical Industries, Ltd. | Nouvellesroteines receptrices couplees aux proteines g, leurs adn et leursigands |
WO2001075104A1 (fr) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Nouvelle proteine, adn codant pour celle-ci, et son procede de production |
WO2002085399A1 (en) | 2001-04-20 | 2002-10-31 | Takeda Chemical Industries, Ltd. | Peptide-containing preparations |
WO2002092829A1 (fr) * | 2001-05-17 | 2002-11-21 | Takeda Chemical Industries, Ltd. | Procede de production d'un peptide |
Non-Patent Citations (8)
Title |
---|
J. SAMBROOK ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LAB. PRESS |
KOTARI, THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 37, 14 September 2001 (2001-09-14), pages 34631 - 34636 |
MASATO KOTANI ET AL.: "The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54", J. BIOL. CHEM., vol. 276, no. 37, 2001, pages 34631 - 34636, XP002262291 * |
MUIR, THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 31, 3 August 2001 (2001-08-03), pages 28969 - 28975 |
RINGEL MATTHEW D. ET AL.: "Metastin receptor is overexpressed in rapillary thyroid cancer and activates MAP kinase in thyroid cancer cells", J. CLIN. ENDOCRINOL. METAB., vol. 87, no. 5, May 2002 (2002-05-01), pages 2399 - 2402, XP002979399 * |
SANG-KYOU HAN ET AL.: "Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by Rf-amide-related peptides through the Galphaq/11 pathway", PROC. NATL. ACAD. SCI. USA, vol. 99, no. 23, November 2002 (2002-11-01), USA, pages 14740 - 14745, XP002979400 * |
See also references of EP1577323A4 |
STAFFORD, CANCER RESEARCH, vol. 62, pages 5399 - 5404 |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8361968B2 (en) | 2002-12-26 | 2013-01-29 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
WO2004060264A2 (en) * | 2003-01-06 | 2004-07-22 | Takeda Pharmaceutical Company Limited | Metastin derivatives and their use |
WO2004060264A3 (en) * | 2003-01-06 | 2004-12-02 | Takeda Pharmaceutical | Metastin derivatives and their use |
US7754220B2 (en) | 2003-03-12 | 2010-07-13 | Takeda Pharmaceutical Company Limited | Methods of inhibiting secretion of follicle-stimulating hormone and testosterone |
EP1750513A4 (en) * | 2004-04-23 | 2009-07-22 | Serono Lab | USE OF GPCR54 LIGANDS FOR THE TREATMENT OF INFERTILITY |
EP1750513A2 (en) * | 2004-04-23 | 2007-02-14 | Applied Research Systems ARS Holding N.V. | Use of gpcr54 ligands for the treatment of infertility |
WO2006001499A3 (en) * | 2004-06-25 | 2006-03-02 | Takeda Pharmaceutical | Metastin derivatives and use thereof |
US8778871B2 (en) | 2004-06-25 | 2014-07-15 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US7625869B2 (en) | 2004-06-25 | 2009-12-01 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
WO2006001499A2 (en) * | 2004-06-25 | 2006-01-05 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
EP2113513A3 (en) * | 2004-06-25 | 2010-11-03 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US7960348B2 (en) | 2005-12-22 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US7786083B2 (en) | 2006-10-25 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US20110059888A1 (en) * | 2006-10-25 | 2011-03-10 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US8765909B2 (en) | 2006-10-25 | 2014-07-01 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
WO2008050897A1 (en) | 2006-10-25 | 2008-05-02 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
WO2009131191A1 (ja) | 2008-04-24 | 2009-10-29 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
WO2010013762A1 (ja) | 2008-07-30 | 2010-02-04 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
EP3210998A1 (en) | 2008-07-30 | 2017-08-30 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
JP2012513982A (ja) * | 2008-12-29 | 2012-06-21 | 武田薬品工業株式会社 | 癌の予防・治療剤 |
US20110312898A1 (en) * | 2008-12-29 | 2011-12-22 | Takeda Pharmaceutical Company Limited | Prophylactic / therapeutic agent for cancer |
WO2010076896A1 (en) | 2008-12-29 | 2010-07-08 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for cancer |
US8716228B2 (en) | 2009-05-27 | 2014-05-06 | Yeda Research And Development Co. Ltd. | GPR54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities |
WO2013017631A1 (en) | 2011-08-04 | 2013-02-07 | Msd Oss B.V. | Kisspeptide-pentasaccharide conjugates |
Also Published As
Publication number | Publication date |
---|---|
US20120015868A1 (en) | 2012-01-19 |
KR20050090420A (ko) | 2005-09-13 |
US8361968B2 (en) | 2013-01-29 |
CN1761680A (zh) | 2006-04-19 |
US20090318365A1 (en) | 2009-12-24 |
CA2511858A1 (en) | 2004-07-29 |
EP1577323A4 (en) | 2008-04-02 |
AU2003292696A1 (en) | 2004-08-10 |
EP1577323A1 (en) | 2005-09-21 |
US20060241051A1 (en) | 2006-10-26 |
EP1577323B1 (en) | 2013-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004063221A1 (ja) | メタスチン誘導体およびその用途 | |
JP4654284B2 (ja) | メタスチン誘導体およびその用途 | |
JP5686825B2 (ja) | メタスチン誘導体およびその用途 | |
JP4653840B2 (ja) | メタスチン誘導体およびその用途 | |
US8404643B2 (en) | Metastin derivatives and use thereof | |
US20110118172A1 (en) | Metastin derivative and use thereof | |
JP4804714B2 (ja) | メタスチン誘導体およびその用途 | |
RU2454425C2 (ru) | Производные метастина и их применение | |
KR20070031949A (ko) | 메타스틴 유도체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2511858 Country of ref document: CA Ref document number: 2003768337 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057012083 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038B0012X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057012083 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003768337 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006241051 Country of ref document: US Ref document number: 10540494 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10540494 Country of ref document: US |